

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A prospective observational study protocol for examining the ability of contrast-enhanced ultrasound to predict sepsis-associated acute kidney injury

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023981
Article Type:	Protocol
Date Submitted by the Author:	09-May-2018
Complete List of Authors:	liu, ning; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhang, Zhongheng Hong, Yucai; emergency medicine Li, Bing Cai, Huabo Zhao, Hui Dai, Junru Liu, Lian Qian, Xin Jin, Qicheng
Keywords:	sepsis, acute kidney injury, contrast-enhanced ultrasound, prediction

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **A prospective observational study protocol for examining the ability**  
5  
6 **of contrast-enhanced ultrasound to predict sepsis-associated acute**  
7  
8 **kidney injury**  
9

10  
11  
12  
13 Ning Liu,<sup>1</sup> Zhongheng Zhang, \*<sup>1</sup> Yucai Hong, <sup>1</sup> Bing Li, <sup>1</sup> Huabo Cai, <sup>1</sup> Hui Zhao,<sup>1</sup>  
14 Junru Dai,<sup>1</sup>Lian Liu,<sup>1</sup> Xin Qian,<sup>1</sup> Qicheng Jin<sup>2</sup>  
15  
16

17  
18 1. Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang  
19 University School of Medicine, Hangzhou, China  
20

21  
22 2. Department of Ultrasound Medicine, Sir Run Run Shaw Hospital, Zhejiang  
23 University School of Medicine, Hangzhou, China  
24

25  
26 \*Corresponding author: Zhongheng Zhang, Department of Emergency Medicine, Sir  
27 Run Run Shaw Hospital, Zhejiang University School of Medicine,  
28 Hangzhou, 310000, China;  
29

30  
31  
32 Tel. : (0571) 88006810  
33

34  
35 Email: [zh\\_zhang1984@zju.edu.cn](mailto:zh_zhang1984@zju.edu.cn)  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Sepsis-associated acute kidney injury (SA-AKI) increases morbidity and mortality among critically ill patients. This study aims to evaluate renal microcirculation perfusion after sepsis using contrast-enhanced ultrasonography (CEUS), and to explore whether CEUS is useful for predicting the risk of developing SA-AKI.

**Methods and analysis:** This prospective observational study will enrol patients who are diagnosed with sepsis and divide them into AKI and non-AKI groups based on the Acute Kidney Injury Network criteria. Conventional ultrasonography and CEUS scans will be performed on days 0, 1, 3, and 7 after admission to the emergency intensive care unit. The CEUS scan data will be used to create time-intensity curves that characterize renal microcirculation, including the blood volume and velocity parameters. Ultrasound results, demographic information, and routine haematology and biochemistry results will be compared between the two groups. We will also assess the patients' survival outcomes in the intensive care unit, at 1 month, at 3 months, at 1 year, and at 2 years after discharge.

**Ethics and dissemination:** The study protocol was approved by the ethics committee of Sir Run Run Shaw Hospital (Zhejiang University Medical College). The results will be published in a peer-reviewed journal and shared with the worldwide medical community.

**Trial registration:** ISRCTN 14728986.

**Strengths and limitations of this study:**

1. This study will be the first to evaluate contrast-enhanced ultrasonography for predicting the risk of sepsis-associated acute kidney injury.
2. This uncomplicated and non-nephrotoxic procedure can be performed at the patient's bedside, which is especially useful in the emergency setting.
3. Subjective differences, patient heterogeneity, and inter-operator variability may limit the generalizability of the findings.

## INTRODUCTION

Sepsis is a syndrome than involves an over-activated systemic inflammatory response to infection. This condition can lead to multiple organ dysfunction, with the kidneys being a commonly involved organ.[1] In the field of critical care, sepsis remains a major cause of death, despite the widespread use of antibiotics and ongoing research to improve resuscitation methods.

Acute kidney injury (AKI) is characterized by the loss of kidney function,[2] and has many aetiologies that include sepsis-associated AKI (SA-AKI), ischemia reperfusion injury, extensive skin burns, severe pancreatitis, diabetic ketoacidosis, and drug poisoning.[3] Sepsis is one of the most common causes of AKI, accounting for 50% of all cases,[4] and SA-AKI is thought to involve microvascular dysfunction during sepsis that leads to both local injury and multiple organ dysfunction. Current epidemiological data indicate that AKI and chronic kidney disease are closely-related, rather than independent conditions, and that they share various risk factors. Moreover, both conditions are risk factors for cardiovascular disease,[5] with SA-AKI causing increased morbidity and mortality among critically ill patients. Thus, early prediction and recognition of SA-AKI are important steps in the early and effective initiation of proper therapy, which can prevent further complications and multiple organ dysfunction. Research regarding the pathogenesis of SA-AKI has mainly focused on inflammation and global renal blood flow, although recent attention has been paid to renal microcirculation alternations. Therefore, early detection of renal

1  
2  
3  
4 microcirculation dysfunction during and after sepsis may facilitate subsequent  
5  
6 treatment and prognostic prediction.  
7

8 Contrast-enhanced ultrasonography (CEUS) is an imaging technique that provides  
9  
10 real-time observations and accurate identification of blood flow to an organ of interest.  
11  
12 Unlike conventional ultrasonography, which cannot visualize small blood vessels and  
13  
14 low-velocity blood flow, CEUS visualizes vessels that feed a lesion or organ as well  
15  
16 as their perfusion status. Thus, CEUS has become widely used in the emergency  
17  
18 department for evaluating cases of abdominal blunt trauma,[6] and is useful for  
19  
20 evaluating microcirculation perfusion in pancreatic, cardiac, hepatic, and renal  
21  
22 transplant applications. However, the use of CEUS in sepsis cases is limited and it  
23  
24 remains unclear whether it can provide useful information for predicting SA-AKI  
25  
26 risk.[7, 8] Therefore, the present study aims to use CEUS at an emergency intensive  
27  
28 care unit (EICU) to evaluate renal microcirculation perfusion after sepsis, as well as  
29  
30 its ability to predict SA-AKI risk.  
31  
32  
33  
34  
35  
36  
37

## 38 **METHODS AND ANALYSIS**

### 39 **Study design**

40  
41 This prospective observational study will enrol patients with sepsis who are treated at  
42  
43 an interdisciplinary EICU (Sir Run Run Shaw Hospital, Zhejiang University) between  
44  
45 August 11, 2017 and September 30, 2019. All patients will be educated regarding the  
46  
47 study's protocol and purposes, and will only be enrolled after receiving written  
48  
49 informed consent from the patient or their family members.  
50  
51  
52  
53

### 54 **Cohort descriptions**

1  
2  
3 Patients with sepsis, severe sepsis, and septic shock will be screened for eligibility if  
4 they are >18 years old. The exclusion criteria are 1) an EICU stay of <24 h or the  
5  
6 presence of a do-not-resuscitate order, 2) the presence of chronic kidney disease and  
7  
8 long-term haemodialysis, 3) critically ill patients who have started renal replacement  
9  
10 therapy because of AKI before their EICU admission, 4) a history of kidney  
11  
12 transplantation, and 5) AKI caused by obstruction. Sepsis is defined as an acute  
13  
14 change of  $\geq 2$  points in the total Sequential Organ Failure Assessment score as a result  
15  
16 of anti-inflammatory function. Septic shock is defined as sepsis with persistent  
17  
18 hypotension requiring vasopressors to maintain a mean arterial pressure of  $\geq 65$   
19  
20 mmHg and serum lactate levels of  $> 2$  mmol/L (18 mg/dL) despite adequate  
21  
22 resuscitation volume.[9]  
23  
24  
25  
26  
27  
28  
29

30 We plan to recruit 200 patients, who will be divided into AKI and non-AKI groups  
31  
32 based on their serum creatinine (SCr) levels. We will consider AKI to be present  
33  
34 when blood urea nitrogen levels are  $> 80$  mg/dL or creatinine levels are  $> 3$  mg/dL.[10,  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Patient and Public Involvement**

No patients were involved in developing plans for design or implementation of the study, nor were they involved in setting the research question or the outcome measures. No patients were requested to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

## Study protocol

Demographic information and chronic disease history will be collected as baseline characteristics during the hospitalization. The Acute Physiology And Chronic Health Evaluation II score will be used to assess the severity of the disease within 24 h after EICU admission. Each patient will be followed for at least 1 week using routine haematology and biochemistry testing for complete blood count, haemoglobin, arterial blood gas, arteriovenous oxygen difference, pro-brain natriuretic peptide, plasma protein, C-reactive protein, SCr, and estimated glomerular filtration rate. Work sheets will also be maintained to record the patients' vital signs (temperature, heart rate, respiration, blood pressure, mean arterial pressure, central venous pressure, SpO<sub>2</sub>), neurological signs (Glasgow coma score, responsiveness, Patient at Risk Score, motor response), medication, intake, and output. The dosage and frequency will be recorded for vasoactive drugs in cases of shock. Conventional ultrasonography and CEUS scans will be performed on days 0, 1, 3, and 7 after EICU admission, although the CEUS examinations will be discontinued if the patient recovers and is transferred to the floor ward or is discharged. All imaging will be performed by highly experienced EICU physicians with >10 years of experience performing bedside ultrasonography. Survival outcomes in the EICU, at 1 month, at 3 months, at 1 year, and at 2 years after discharge will be determined using outpatient visits or telephone interviews.

## Conventional ultrasonography

1  
2  
3  
4 Conventional two-dimensional ultrasonography scans will be performed using a 3.5–5  
5  
6 MHz convex ultrasound probe (Mindray M9, China) to evaluate the size, morphology,  
7  
8 and macrovascular supply of the kidneys, which will be consistently imaged in the  
9  
10 longitudinal plane. Colour Doppler flow imaging will be used to evaluate the peak  
11  
12 systolic velocity, resistance index, and end diastolic velocities of the segmental artery,  
13  
14 interlobar artery, and arcuate artery. Cardiac and lung functions will be assessed using  
15  
16 echocardiography and lung ultrasonography, with data including the left ventricular  
17  
18 ejection fraction, E-point to septal separation, B lines of the lung, and the respiratory  
19  
20 variation of the inferior vena cava diameter.  
21  
22  
23  
24

## 25 **CEUS**

26  
27  
28 The CEUS will be performed immediately after the long-axis view of the kidney has  
29  
30 been obtained using conventional ultrasonography. SonoVue® is a commercial  
31  
32 ultrasound contrast agent (Bracco, Milan, Italy) that will be administered  
33  
34 intravascularly with a bolus of 1–2.4 mL based on the patient's weight, height, and  
35  
36 age. The bolus will then be followed by a 10-mL injection of physiological saline via  
37  
38 a peripheral antecubital vein. The timer and imaging recorder will be activated  
39  
40 simultaneously with the contrast agent injection, and the procedure will last for a total  
41  
42 of 4–6 min. A lower mechanical index will be applied, although the mechanical  
43  
44 parameters will be standardized for all patients. We will manually define three  
45  
46 circular regions of interest (diameters of 1.5–2.0 cm) at the renal cortex and medulla,  
47  
48 which are at the same approximate location, to analyse renal microcirculation  
49  
50 perfusion. Care will be taken to avoid nearby vessels (Figure 1).  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 The two phase terms will be the cortical phases (from 10–15 s after injection until  
5  
6 30–45 s) and the medullary phases (approximately 30–45 s after injection until the  
7  
8 microbubble echoes disappear completely).[12] The renal cortex may become  
9  
10 enhanced earlier than the renal medulla, and a second contrast agent injection will be  
11  
12 performed at an interval of approximately 15 min if necessary. In that scenario, the  
13  
14 microbubbles should be destroyed during the interval using the highest acoustic  
15  
16 power setting. Images and video clips from the CEUS will be digitally stored for  
17  
18 subsequent quantitative analysis.  
19  
20  
21

22  
23 The time-intensity curves will be created using software to analyse blood volume and  
24  
25 velocity based on the following parameters: baseline intensity (intensity before the  
26  
27 contrast agent arrives in the microcirculation), arrival time (the time when the contrast  
28  
29 agent appears), time-to-peak (the time to the maximum contrast intensity), peak  
30  
31 intensity (the maximum contrast intensity value), ascending slope, descending time/2,  
32  
33 descending slope, and area under the curve (Figure 2).[13]  
34  
35  
36

### 37 **Statistical analysis**

38  
39  
40 All statistical analyses will be performed using SPSS software (version 17.0; SPSS  
41  
42 Inc., Chicago, IL) and MedCalc® software (Mariakerke, Belgium). Differences will  
43  
44 be considered statistically significant at two-tailed *P*-values of <0.05. Categorical data  
45  
46 will be compared using the chi-square test. Continuous data will be reported as mean  
47  
48 ± standard deviation and compared using Student's *t* test.[14] Variables that are  
49  
50 significant in the univariate analyses will be included in multivariate logistic  
51  
52 regression analysis.[15] A receiver operating characteristic curve will also be created  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 to examine the ability of CEUS to predict AKI based on the sensitivity, specificity,  
4 accuracy, positive predictive, and negative predictive values.  
5  
6

### 7 8 **Follow up study** 9

10 Non-invasive measurements of cardiovascular functions and peripheral tissue  
11 oxygenation may be useful for critically ill patients. Transcutaneous oxygen pressure  
12 (TcPO<sub>2</sub>) is a non-invasive and convenient way to detect tissue ischemia or inadequate  
13 perfusion, and may help evaluate microcirculation perfusion and predict fluid  
14 responsiveness during the follow-up of patients with SA-AKI.[16, 17] During sepsis,  
15 the skin is the simplest and most convenient tissue for evaluating microcirculation  
16 perfusion and treatment effectiveness, as it is prone to vasoconstriction during shock  
17 and is the last tissue to recover perfusion after fluid resuscitation. Furthermore, skin  
18 oxygenation can be monitored using TcPO<sub>2</sub>, which might better reflect PaO<sub>2</sub> than  
19 SaO<sub>2</sub>. [18] Moreover, TcPO<sub>2</sub> is closely related to PaO<sub>2</sub> during anaesthesia [19] and can  
20 accurately reflect local ischemic and global shock.[16] Therefore, we want to explore  
21 whether the combination of CEUS and TcPO<sub>2</sub> could be useful for evaluating the  
22 microcirculation during SA-AKI, which can facilitate early and effective treatment in  
23 the patients with circulatory failure.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **DISCUSSION** 45

46 AKI is common among critically ill patients and is an important cause of ICU  
47 admission with significant morbidity and mortality. The incidence of AKI in the ICU  
48 is approximately 55–60% and the mortality rate is approximately 27%.[20] Although  
49 AKI is manageable, progression to chronic renal failure can lead to tremendous  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 psychological and economic burdens on the patient. Thus, many studies have  
5  
6 explored biomarkers for predicting AKI development among critically ill patients,  
7  
8 although those studies have revealed limited predictive values.[21-23]  
9  
10 To the best of our knowledge, SA-AKI is a common condition that lacks an effective  
11  
12 therapy. Continuous renal replacement therapy (CRRT) is an useful method for  
13  
14 managing AKI,[24] although improvements in CRRT have failed to reduce the high  
15  
16 mortality rate among patients with AKI.[25] This lack of efficacy can be related to the  
17  
18 patient's status and the timing of CRRT,[26] with recent studies indicating that early  
19  
20 CRRT can improve the patient's prognosis. However, there is no specific definition of  
21  
22 early CRRT initiation, with some studies defining the timing of CRRT initiation as  
23  
24 during the "high risk" stage or the "early injury period".[27] Therefore, it is important  
25  
26 to identify a method that can predict SA-AKI risk and facilitate CRRT as early as  
27  
28 possible, which could improve outcomes among patients with severe sepsis.[28]  
29  
30 The underlying pathophysiology of SA-AKI is complex and multifactorial, although  
31  
32 recent studies have indicated that it may be related to microvascular dysfunction that  
33  
34 leads to the release of microparticles, inflammatory mediators, and cytokines. For  
35  
36 example, patients at high risk of developing SA-AKI have increased levels of  
37  
38 microparticles,[29] vascular endothelial growth factor,[30] and endothelial progenitor  
39  
40 cells.[31] These biomarkers can predict the occurrence of AKI and are useful during  
41  
42 the monitoring of treatment response. However, these pathways and biomarkers have  
43  
44 only been evaluated in the pre-clinical stage, and additional research is needed to  
45  
46 verify their clinical utility.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Patients with SA-AKI exhibit altered blood flow to the macrovascular and  
5  
6 microvasculature beds, with the most obvious pathophysiological change being  
7  
8 microvascular dysfunction.[32] The main feature of microvascular dysfunction leads  
9  
10 to the decreased nutrient delivery capillaries, which may play an important role in the  
11  
12 development of hypoxia and multiple organ dysfunction during SA-AKI.[33, 34]  
13  
14 Thus, CEUS may be useful for providing continuous real-time monitoring of the  
15  
16 capillary microcirculation, and this ability is enhanced with the use of ultrasound  
17  
18 contrast agents.[35] SonoVue® is a second-generation contrast agent that is  
19  
20 composed of sulphur hexafluoride-filled microbubbles (2–10 µm), and is considered  
21  
22 an ideal intravascular tracer that facilitates more sensitive, accurate, and non-invasive  
23  
24 evaluation of capillary perfusion. Furthermore, sulphur hexafluoride is not  
25  
26 nephrotoxic [35] and can be completely eliminated via the lungs within a few minutes  
27  
28 after its injection, which is unlike the traditional nephrotoxic contrast agents that are  
29  
30 used during computed tomography and magnetic resonance imaging. Finally, the  
31  
32 phospholipid shell of the SonoVue® microbubbles is very compliant and is not  
33  
34 destroyed at a low mechanical index (<0.16) during CEUS.[35]  
35  
36  
37 A map of the kidney microvasculature can be provided with high temporal and spatial  
38  
39 resolution using CEUS,[7] and three-dimensional CEUS can provide detailed  
40  
41 information regarding abnormal blood flow based on perfusion volumes or lack  
42  
43 thereof. For example, Dong et al. have indicated that CEUS might provide clinically  
44  
45 useful tissue perfusion data for the early diagnosis of diabetic nephropathies using  
46  
47 quantitative evaluation of renal cortex perfusion.[36] Furthermore, CEUS is widely  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 used in the dynamic assessment of postoperative complications, such as tissue  
4  
5  
6 hypoperfusion, vessel stenosis, dilatation or embolization, active bleeding, and the  
7  
8 development of inflammation or infection.[37, 38] Tumour microvasculature and  
9  
10 angiogenesis can also be assessed using CEUS,[39] and Fischer et al. have reported  
11  
12 that CEUS was superior to traditional ultrasonography for identifying acute rejection  
13  
14 after renal transplantation.[40] Wang et al. have also recently evaluated CEUS for  
15  
16 monitoring renal microcirculation after kidney transplantation,[41] and suggested that  
17  
18 peak systolic velocity, end diastolic velocity, resistance index, and pulsatility index  
19  
20 from colour Doppler ultrasound scans could not differentiate between patients with  
21  
22 normal and abnormal SCr levels. However, CEUS in that study revealed a significant  
23  
24 inter-group difference in the renal parenchymal microcirculation, with the  
25  
26 CEUS-based perfusion index of the transplanted kidney being correlated with renal  
27  
28 function. Nevertheless, there are limited reports regarding the application of CEUS  
29  
30 among patients with SA-AKI, and the present study revealed that CEUS could be  
31  
32 combined with the SonoVue® agent, specific regions of interest, and the  
33  
34 time-intensity curve to dynamically analyse renal microcirculation perfusion. This  
35  
36 information may be useful for predicting the risk of developing AKI after sepsis,  
37  
38 which could facilitate early and effective treatment that may improve the patient's  
39  
40 prognosis.

41  
42  
43  
44  
45  
46  
47  
48  
49  
50 The use of CEUS for evaluating renal microcirculation has several important  
51  
52 advantages, such as being a relatively uncomplicated procedure that can be performed  
53  
54 at the patient's bedside during emergency management. In addition, there is no  
55  
56  
57  
58  
59  
60

1  
2  
3 exposure to radiation or risk of nephrotoxicity, which can impair renal perfusion and  
4  
5 increase the risk of nephrogenic systemic fibrosis. Moreover, CEUS is safe for  
6  
7 patients of all ages, including children, critically ill patients, and older individuals.  
8  
9  
10 The Food and Drug Administration has approved CEUS for use in paediatric patients,  
11  
12 and ongoing clinical studies are evaluating the safety of the SonoVue® agent in this  
13  
14 setting.[42] Finally, CEUS overcomes the shortcomings of conventional B-mode  
15  
16 sonography, which cannot detect small blood vessels and has poor sensitivity at low  
17  
18 velocities and amplitudes.  
19  
20  
21

22  
23 The present study also has several limitations that will need to be considered. For  
24  
25 example, individual-level differences may limit the generalizability of the results, and  
26  
27 hypothermia is known to alter blood flow and ultimately the distribution of the  
28  
29 contrast agent.[43] However, the present study will be unable to determine whether  
30  
31 heart rate, blood pressure, pulmonary artery pressure, or cardiac chamber pressure  
32  
33 affect enhancement after the contrast agent injection. In addition, inter-operator  
34  
35 variability may affect the findings, which we considered a subjective error. Third,  
36  
37 there is a fairly long interval between the CEUS examinations, which may delay the  
38  
39 diagnosis in patients who develop SA-AKI.  
40  
41  
42  
43

44  
45 In conclusion, the present study aims to use CEUS to evaluate renal microcirculation  
46  
47 changes in patients with and without AKI, which should provide information  
48  
49 regarding whether CEUS can predict the risk of developing SA-AKI.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Contributors:** All listed authors have participated in the study, and have reviewed and approved the submitted manuscript. NL, ZZ, and YH designed this study. JD, PZ, SL, LL, BZ, XQ, and QJ drafted and submitted the report. HC, HZ, BL, YZ, and LX revised the report.

**Funding:** The study was supported by the Zhejiang Provincial Natural Science Foundation of China (LGF18H150005) and Scientific research project of Zhejiang Education Commission (Y201737841).

**Competing interests:** None declared.

**Ethics approval:** The study protocol was approved by the ethics committee of Sir Run Run Shaw Hospital (Zhejiang University Medical College).

**Provenance and peer review:** Not commissioned, externally peer reviewed.

## REFERENCES

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Critical care medicine* 2001;**29**(7):1303-10
2. Section 2: AKI Definition. *Kidney international supplements* 2012;**2**(1):19-36 doi: 10.1038/kisup.2011.32[published Online First: Epub Date].
3. Zhang Z. Biomarkers, diagnosis and management of sepsis-induced acute kidney injury: a narrative review. *Heart, lung and vessels* 2015;**7**(1):64-73
4. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *Jama* 2005;**294**(7):813-8 doi: 10.1001/jama.294.7.813[published Online First: Epub Date].
5. Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. *The New England journal of medicine* 2014;**371**(1):58-66 doi: 10.1056/NEJMra1214243[published Online First: Epub Date].
6. Zhang Z, Hong Y, Liu N, et al. Diagnostic accuracy of contrast enhanced ultrasound in patients with blunt abdominal trauma presenting to the emergency department: a systematic review and meta-analysis. *Scientific reports* 2017;**7**(1):4446 doi: 10.1038/s41598-017-04779-2[published Online First: Epub Date].
7. Harvey CJ, Sidhu PS, Bachmann Nielsen M. Contrast-enhanced ultrasound in

- 1  
2  
3 renal transplants: applications and future directions. *Ultraschall in der*  
4 *Medizin* 2013;**34**(4):319-21 doi: 10.1055/s-0033-1350138[published  
5 Online First: Epub Date]].
- 6  
7 8. Fernandez CP, Ripolles T, Martinez MJ, et al. Diagnosis of acute cortical necrosis  
8 in renal transplantation by contrast-enhanced ultrasound: a preliminary  
9 experience. *Ultraschall in der Medizin* 2013;**34**(4):340-4 doi:  
10 10.1055/s-0032-1313007[published Online First: Epub Date]].
- 11  
12 9. Singer M, Deutschman CS, Seymour CW, et al. The Third International  
13 Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama*  
14 2016;**315**(8):801-10 doi: 10.1001/jama.2016.0287[published Online  
15 First: Epub Date]].
- 16  
17 10. Mizuno T, Sato W, Ishikawa K, et al. KDIGO (Kidney Disease: Improving Global  
18 Outcomes) criteria could be a useful outcome predictor of  
19 cisplatin-induced acute kidney injury. *Oncology* 2012;**82**(6):354-9 doi:  
20 10.1159/000338664[published Online First: Epub Date]].
- 21  
22 11. Ad-hoc working group of E, Fliser D, Laville M, et al. A European Renal Best  
23 Practice (ERBP) position statement on the Kidney Disease Improving  
24 Global Outcomes (KDIGO) clinical practice guidelines on acute kidney  
25 injury: part 1: definitions, conservative management and  
26 contrast-induced nephropathy. *Nephrology, dialysis, transplantation :*  
27 *official publication of the European Dialysis and Transplant Association -*  
28 *European Renal Association* 2012;**27**(12):4263-72 doi:  
29 10.1093/ndt/gfs375[published Online First: Epub Date]].
- 30  
31 12. Harvey CJ, Alsafi A, Kuzmich S, et al. Role of US Contrast Agents in the  
32 Assessment of Indeterminate Solid and Cystic Lesions in Native and  
33 Transplant Kidneys. *Radiographics : a review publication of the*  
34 *Radiological Society of North America, Inc* 2015;**35**(5):1419-30 doi:  
35 10.1148/rg.2015140222[published Online First: Epub Date]].
- 36  
37 13. Dietrich CF, Averkiou MA, Correas JM, et al. An EFSUMB introduction into  
38 Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of  
39 tumour perfusion. *Ultraschall in der Medizin* 2012;**33**(4):344-51 doi:  
40 10.1055/s-0032-1313026[published Online First: Epub Date]].
- 41  
42 14. Zhang Z. Univariate description and bivariate statistical inference: the first  
43 step delving into data. *Annals of translational medicine* 2016;**4**(5):91 doi:  
44 10.21037/atm.2016.02.11[published Online First: Epub Date]].
- 45  
46 15. Zhang Z. Model building strategy for logistic regression: purposeful selection.  
47 *Annals of translational medicine* 2016;**4**(6):111 doi:  
48 10.21037/atm.2016.02.15[published Online First: Epub Date]].
- 49  
50 16. Yu M, Morita SY, Daniel SR, et al. Transcutaneous pressure of oxygen: a  
51 noninvasive and early detector of peripheral shock and outcome. *Shock*  
52 2006;**26**(5):450-6 doi: 10.1097/01.shk.0000228798.18174.6a[published  
53 Online First: Epub Date]].
- 54  
55 17. Chapital AD, Yu M, Ho HC, et al. Using transcutaneous oxygen pressure  
56 measurements as selection criteria for activated protein C use. *The*  
57  
58  
59

- Journal of trauma 2008;**65**(1):30-3 doi:  
10.1097/TA.0b013e3180eeab28[published Online First: Epub Date]].
18. Nishiyama T, Nakamura S, Yamashita K. Effects of the electrode temperature of a new monitor, TCM4, on the measurement of transcutaneous oxygen and carbon dioxide tension. *Journal of anesthesia* 2006;**20**(4):331-4 doi: 10.1007/s00540-006-0422-9[published Online First: Epub Date]].
19. McDowell JW. Correlation of arterial and transcutaneous po2s following wet and dry calibration techniques: a comparison study. *Respiratory care* 1981;**26**(7):649-52
20. Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive care medicine* 2015;**41**(8):1411-23 doi: 10.1007/s00134-015-3934-7[published Online First: Epub Date]].
21. Zhang Z, Lu B, Ni H, et al. Microalbuminuria can predict the development of acute kidney injury in critically ill septic patients. *Journal of nephrology* 2013;**26**(4):724-30 doi: 10.5301/jn.5000231[published Online First: Epub Date]].
22. Zhang Z, Lu B, Sheng X, et al. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. *American journal of kidney diseases : the official journal of the National Kidney Foundation* 2011;**58**(3):356-65 doi: 10.1053/j.ajkd.2011.02.389[published Online First: Epub Date]].
23. Zhang Z, Xu X, Fan H, et al. Higher serum chloride concentrations are associated with acute kidney injury in unselected critically ill patients. *BMC nephrology* 2013;**14**:235 doi: 10.1186/1471-2369-14-235[published Online First: Epub Date]].
24. Zhang Z, Xu X, Zhu H. Intensive- vs less-intensive-dose continuous renal replacement therapy for the intensive care unit-related acute kidney injury: a meta-analysis and systematic review. *Journal of critical care* 2010;**25**(4):595-600 doi: 10.1016/j.jcrc.2010.05.030[published Online First: Epub Date]].
25. Oh HJ, Park JT, Kim JK, et al. Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2012;**27**(2):589-94 doi: 10.1093/ndt/gfr307[published Online First: Epub Date]].
26. Oh HJ, Lee MJ, Kim CH, et al. The benefit of specialized team approaches in patients with acute kidney injury undergoing continuous renal replacement therapy: propensity score matched analysis. *Critical care* 2014;**18**(4):454 doi: 10.1186/s13054-014-0454-8[published Online First: Epub Date]].
27. Demirkilic U, Kuralay E, Yenicesu M, et al. Timing of replacement therapy for acute renal failure after cardiac surgery. *Journal of cardiac surgery* 2004;**19**(1):17-20

- 1  
2  
3 28. Oh HJ, Kim MH, Ahn JY, et al. Can early initiation of continuous renal  
4 replacement therapy improve patient survival with septic acute kidney  
5 injury when enrolled in early goal-directed therapy? *Journal of critical*  
6 *care* 2016;**35**:51-6 doi: 10.1016/j.jcrc.2016.04.032[published Online First:  
7 Epub Date]].
- 8  
9 29. Zafrani L, Gerotziafas G, Byrnes C, et al. Calpastatin controls polymicrobial  
10 sepsis by limiting procoagulant microparticle release. *American journal of*  
11 *respiratory and critical care medicine* 2012;**185**(7):744-55 doi:  
12 10.1164/rccm.201109-1686OC[published Online First: Epub Date]].
- 13  
14 30. Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular  
15 endothelial growth factor in alloimmunity. *The Journal of clinical*  
16 *investigation* 2003;**112**(11):1655-65 doi: 10.1172/JCI17712[published  
17 Online First: Epub Date]].
- 18  
19 31. Patschan SA, Patschan D, Temme J, et al. Endothelial progenitor cells (EPC) in  
20 sepsis with acute renal dysfunction (ARD). *Critical care* 2011;**15**(2):R94  
21 doi: 10.1186/cc10100[published Online First: Epub Date]].
- 22  
23 32. Lehr HA, Bittinger F, Kirkpatrick CJ. Microcirculatory dysfunction in sepsis: a  
24 pathogenetic basis for therapy? *The Journal of pathology*  
25 2000;**190**(3):373-86 doi:  
26 10.1002/(SICI)1096-9896(200002)190:3<373::AID-PATH593>3.0.CO;2-3  
27 [published Online First: Epub Date]].
- 28  
29 33. Spronk PE, Zandstra DF, Ince C. Bench-to-bedside review: sepsis is a disease  
30 of the microcirculation. *Critical care* 2004;**8**(6):462-8 doi:  
31 10.1186/cc2894[published Online First: Epub Date]].
- 32  
33 34. Trzeciak S, Rivers EP. Clinical manifestations of disordered microcirculatory  
34 perfusion in severe sepsis. *Critical care* 2005;**9 Suppl 4**:S20-6 doi:  
35 10.1186/cc3744[published Online First: Epub Date]].
- 36  
37 35. Greis C. Technical aspects of contrast-enhanced ultrasound (CEUS)  
38 examinations: tips and tricks. *Clinical hemorheology and microcirculation*  
39 2014;**58**(1):89-95 doi: 10.3233/CH-141873[published Online First: Epub  
40 Date]].
- 41  
42 36. Dong Y, Wang WP, Lin P, et al. Assessment of renal perfusion with  
43 contrast-enhanced ultrasound: Preliminary results in early diabetic  
44 nephropathies. *Clinical hemorheology and microcirculation*  
45 2016;**62**(3):229-38 doi: 10.3233/CH-151967[published Online First:  
46 Epub Date]].
- 47  
48 37. Gocze I, Wohlgemuth WA, Schlitt HJ, et al. Contrast-enhanced ultrasonography  
49 for bedside imaging in subclinical acute kidney injury. *Intensive care*  
50 *medicine* 2014;**40**(3):431 doi: 10.1007/s00134-013-3152-0[published  
51 Online First: Epub Date]].
- 52  
53 38. Sessa B, Trinci M, Ianniello S, et al. Blunt abdominal trauma: role of  
54 contrast-enhanced ultrasound (CEUS) in the detection and staging of  
55 abdominal traumatic lesions compared to US and CE-MDCT. *La Radiologia*  
56 *medica* 2015;**120**(2):180-9 doi: 10.1007/s11547-014-0425-9[published  
57  
58  
59  
60

- 1  
2  
3 Online First: Epub Date]].
- 4 39. Reimann R, Rubenthaler J, Hristova P, et al. Characterization of histological  
5 subtypes of clear cell renal cell carcinoma using contrast-enhanced  
6 ultrasound (CEUS). *Clinical hemorheology and microcirculation*  
7 2015;**63**(1):77-87 doi: 10.3233/CH-152009[published Online First: Epub  
8 Date]].
- 9  
10 40. Fischer T, Muhler M, Kroncke TJ, et al. Early postoperative ultrasound of  
11 kidney transplants: evaluation of contrast medium dynamics using  
12 time-intensity curves. *RoFo : Fortschritte auf dem Gebiete der*  
13 *Rontgenstrahlen und der Nuklearmedizin* 2004;**176**(4):472-7 doi:  
14 10.1055/s-2004-812992[published Online First: Epub Date]].
- 15  
16 41. Wang X, Yu Z, Guo R, et al. Assessment of postoperative perfusion with  
17 contrast-enhanced ultrasonography in kidney transplantation.  
18 *International journal of clinical and experimental medicine*  
19 2015;**8**(10):18399-405
- 20  
21 42. Rosado E, Riccabona M. Off-Label Use of Ultrasound Contrast Agents for  
22 Intravenous Applications in Children: Analysis of the Existing Literature.  
23 *Journal of ultrasound in medicine : official journal of the American*  
24 *Institute of Ultrasound in Medicine* 2016;**35**(3):487-96 doi:  
25 10.7863/ultra.15.02030[published Online First: Epub Date]].
- 26  
27 43. Hyvelin JM, Tardy I, Arbogast C, et al. Use of ultrasound contrast agent  
28 microbubbles in preclinical research: recommendations for small animal  
29 imaging. *Investigative radiology* 2013;**48**(8):570-83 doi:  
30 10.1097/RLI.0b013e318289f854[published Online First: Epub Date]].
- 31  
32  
33  
34  
35

## 36 FIGURE LEGENDS

37  
38 **Figure 1:** A color-coded map with circular regions of interest (ROIs) at the renal cortex  
39 and medulla.

40  
41  
42  
43 **Figure 2:** A color-coded graph comparing the quantitative contrast-enhanced ultrasound  
44 parameters between the groups with and without acute kidney injury. GOF: goodness of fit,  
45 BI: baseline intensity, AT: arrival time, TTP: time-to-peak, PI: peak intensity, AS:  
46 ascending slope, DT/2: descending time/2, DS: descending slope, AUC: area under the  
47 curve.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: A color-coded map with circular regions of interest (ROIs) at the renal cortex and medulla.

106x73mm (300 x 300 DPI)




Figure 2: A color-coded graph comparing the quantitative contrast-enhanced ultrasound parameters between the groups with and without acute kidney injury. GOF: goodness of fit, BI: baseline intensity, AT: arrival time, TTP: time-to-peak, PI: peak intensity, AS: ascending slope, DT/2: descending time/2, DS: descending slope, AUC: area under the curve.

106x73mm (300 x 300 DPI)

# BMJ Open

## A prospective observational study protocol for examining the ability of contrast-enhanced ultrasonography to predict sepsis-associated acute kidney injury

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023981.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Oct-2018
Complete List of Authors:	liu, ning; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhang, Zhongheng; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Hong, Yucai; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, emergency medicine Li, Bing; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Cai, Huabo; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Zhao, Hui; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Dai, Junru; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Liu, Lian; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Qian, Xin; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Jin, Qicheng; Department of Ultrasound Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Renal medicine
Keywords:	sepsis, acute kidney injury, prediction, contrast-enhanced ultrasonography

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **A prospective observational study protocol for examining the ability of**  
5  
6 **contrast-enhanced ultrasonography to predict sepsis-associated acute**  
7  
8 **kidney injury**  
9  
10

11  
12  
13  
14 Ning Liu,<sup>1</sup> Zhongheng Zhang, \*<sup>1</sup> Yucai Hong, <sup>1</sup> Bing Li,<sup>1</sup> Huabo Cai,<sup>1</sup> Hui Zhao,<sup>1</sup> Junru  
15  
16 Dai,<sup>1</sup> Lian Liu,<sup>1</sup> Xin Qian,<sup>1</sup> Qicheng Jin<sup>2</sup>  
17

18  
19 1. Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University  
20  
21 School of Medicine, Hangzhou, China  
22

23 2. Department of Ultrasound Medicine, Sir Run Run Shaw Hospital, Zhejiang University  
24  
25 School of Medicine, Hangzhou, China  
26

27  
28 \*Corresponding author: Zhongheng Zhang, Department of Emergency Medicine, Sir Run  
29  
30 Run Shaw Hospital, Zhejiang University School of Medicine,  
31  
32 Hangzhou, 310000, China; Tel.: (0571) 88006810; Email: zh\_zhang1984@zju.edu.cn  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Sepsis-associated acute kidney injury (SA-AKI) increases morbidity and mortality among critically ill patients. This study aims to evaluate renal microcirculation perfusion during sepsis using contrast-enhanced ultrasonography (CEUS), and to explore whether CEUS is useful for predicting the risk of developing SA-AKI and severe SA-AKI occurrence .

**Methods and analysis:** This prospective observational study will enroll patients who are diagnosed with sepsis-3 definition. Conventional ultrasonography and CEUS scans will be performed on days 0, 1, 3, and 7 after admission to the emergency intensive care unit. In 7 days later, the total of septic patients were stratified into AKI (including stage 1, 2, and 3 ) and non-AKI groups according to Kidney Disease Improving Global Outcomes (KDIGO) criteria for further statistical analysis. The CEUS scan datas will be used to create time-intensity curves that characterize renal microcirculation, including the blood volume and velocity parameters. Ultrasonography results, demographic information, laboratory and other clinical datas will be compared. We will also assess the patients' survival outcomes in the intensive care unit, at 1 month, at 3 months, at 1 year, and at 2 years after discharge.

**Ethics and dissemination:** The study protocol was approved by the ethics committee of Sir Run Run Shaw Hospital (Zhejiang University Medical College). The results will be published in a peer-reviewed journal and shared with the worldwide medical community.

1  
2  
3  
4 **Trial registration:** ISRCTN 14728986.  
5  
6  
7

8  
9 **Strengths and limitations of this study:**  
10

- 11  
12 1. This study will be the first to evaluate renal perfusion (including cortex and medullary)  
13  
14 in patients with sepsis during their first 7 days of care using contrast-enhanced  
15  
16 ultrasonography for predicting the risk of sepsis-associated acute kidney injury and its  
17  
18 severity.  
19  
20  
21  
22 2. This uncomplicated and non-nephrotoxic procedure with the ability to detect subtle  
23  
24 perfusion abnormalities quickly and in real-time has advantages over traditional modes ,  
25  
26 which is especially useful in the emergency setting.  
27  
28  
29  
30 3. Subjective differences and patient heterogeneity may limit the generalizability of the  
31  
32 findings.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Sepsis is a syndrome than involves an over-activated systemic inflammatory response to infection. This condition can lead to multiple organ dysfunction, with the kidneys being a commonly involved organ[1 2]. In the field of critical care, sepsis remains a major cause of mortality , despite the widespread use of antibiotics and ongoing research to improve resuscitation methods.

Acute kidney injury (AKI) is characterized by the loss of kidney function,[3] and has many aetiologies that include SA-AKI, ischemia reperfusion injury, extensive skin burns, severe pancreatitis, diabetic ketoacidosis, and drug poisoning.[4] Sepsis is one of the most common causes of AKI, accounting for 50% of all cases.[5] Many studies revealed that the possible pathophysiology of SA-AKI is profoundly different from AKI of other etiologies and SA-AKI is thought to involve macrovascular and microvascular dysfunction during sepsis that leads to both local injury and multiple organ dysfunction. Current epidemiological data indicate that SA-AKI and chronic kidney disease are closely-related, rather than independent conditions, and that even a mild or short-term of SA-AKI have tended to develop into chronic and end-stage kidney disease in the near future[6-8] ,with causing increased morbidity and mortality among critically ill patients. Thus, early prediction and recognition of SA-AKI are important steps in the early and effective initiation of proper therapy, which can prevent further complications and multiple organ dysfunction. Research regarding the pathogenesis of SA-AKI has mainly focused on inflammation and global renal blood flow, although recent attention has been

1  
2  
3  
4 paid to renal microcirculation alternations. Therefore, early detection of renal  
5  
6 microcirculation dysfunction during and after sepsis may facilitate subsequent treatment  
7  
8 and prognostic prediction.  
9

10  
11 Contrast-enhanced ultrasonography (CEUS) is an imaging technique that provides  
12  
13 real-time observations and accurate identification of blood flow to an organ of interest.  
14  
15 Unlike conventional ultrasonography, which cannot visualize small blood vessels and  
16  
17 low-velocity blood flow, CEUS visualizes vessels that feed a lesion or organ as well as  
18  
19 their perfusion status. Thus, CEUS has become widely used in the emergency department  
20  
21 for evaluating cases of abdominal blunt trauma,[9] and is useful for evaluating  
22  
23 microcirculation perfusion in pancreatic, cardiac, hepatic, and renal transplant  
24  
25 applications. However, the use of CEUS in sepsis cases is limited and it remains unclear  
26  
27 whether it can provide useful information for predicting SA-AKI risk.[10 11]  
28  
29

30  
31 Therefore, as a primary objective , the present study aims to use CEUS at an emergency  
32  
33 intensive care unit (EICU) to evaluate renal microcirculation perfusion (including cortex  
34  
35 and medullary) in the first 7 days of being diagnosed with sepsis. As a second objective,  
36  
37 we expected to propose some gold standard parameters which is associated with  
38  
39 increasing disorders in renal perfusion in four categories (no AKI, SA- AKI stage 1, stage  
40  
41 2, stage 3) .  
42  
43  
44  
45  
46  
47  
48  
49

## 50 **METHODS AND ANALYSIS**

### 51 **Study design**

1  
2  
3  
4 This prospective observational study will enroll patients with sepsis who are treated at an  
5  
6 interdisciplinary EICU (Sir Run Run Shaw Hospital, Zhejiang University) between  
7  
8 August 11, 2017 and September 30, 2019. All conscious patients will be educated  
9  
10 regarding the study's protocol and purposes, and will be enrolled after receiving written  
11  
12 informed consent from the patient or their family members if patients were ventilated and  
13  
14 sedated.  
15  
16  
17  
18

### 19 **Cohort descriptions and definitions**

20  
21 Patients with sepsis and septic shock will be screened for eligibility if they are >18 years  
22  
23 old. The exclusion criteria are 1) an expected stay of <24 h, 2) the presence of end-stage  
24  
25 kidney disease or long-term haemodialysis, 3) critically ill patients who have started renal  
26  
27 replacement therapy because of SA-AKI before their EICU admission, 4) a history of  
28  
29 kidney transplantation, and 5) SA-AKI caused by obstruction.  
30  
31  
32  
33

34  
35 Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host  
36  
37 response to infection. For clinical operationalization, organ dysfunction can be  
38  
39 represented by an acute change of  $\geq 2$  points in the total Sequential Organ Failure  
40  
41 Assessment score. Septic shock is defined as sepsis with persistent hypotension requiring  
42  
43 vasopressors to maintain a mean arterial pressure of  $\geq 65$  mmHg and serum lactate  
44  
45 levels of  $> 2$  mmol/L (18 mg/dL) despite adequate resuscitation volume.[1]  
46  
47  
48  
49

50  
51 We plan to recruit 200 patients.

52  
53 In order to identify patients with SA-AKI as early as possible, we could apply the Kidney  
54  
55 Disease Improving Global Outcomes (KDIGO) guidelines to our subjects, which  
56  
57  
58  
59

stratifies SA-AKI in three different stages according to changes in creatinine and urine output (Table 1)[12]. Baseline creatinine value ( $\mu\text{mol/L}$ ) was either registered from 6 months previous clinical files or estimated, when data was not available from clinical records, by solving the Modification of Diet in Renal Disease (MDRD) equation assuming a glomerular filtration rate of  $75 \text{ ml/min/1.73 m}^2$ [13 14]

**Table 1** Staging of Sepsis-Associated Acute Kidney Injury (SA-AKI)

Stage	Serum Creatinine	Urine Output
1	1.5–1.9 times baseline OR $\geq 0.3 \text{ mg/dl}$ ( $\geq 265 \text{ mmol/l}$ ) increase	$< 0.5 \text{ ml/kg/h}$ for 6–12 hours
2	2.0–2.9 times baseline	$< 0.5 \text{ ml/kg/h}$ for $\geq 12$ hours
3	3.0 times baseline OR Increase in serum creatinine to $\geq 4.0 \text{ mg/dl}$ ( $\geq 353.6 \text{ mmol/l}$ ) OR Initiation of renal replacement therapy OR, In patients $< 18$ years, decrease in eGFR to $< 35 \text{ ml/min per } 1.73 \text{ m}^2$	$< 0.3 \text{ ml/kg/h}$ for $\geq 24$ hours OR Anuria for $\geq 12$ hours

eGFR: estimated glomerular filtration rate

### Patient and Public Involvement

No patients were involved in developing plans for design or implementation of the study, nor were they involved in setting the research question or the outcome measures. No patients were requested to advise on interpretation or writing up of results. There are no

1  
2  
3  
4 plans to disseminate the results of the research to study participants or the relevant patient  
5  
6 community.  
7

### 8 9 **Study protocol**

10  
11 Demographic information and chronic disease history will be collected as baseline  
12  
13 characteristics during the hospitalization. The Acute Physiology And Chronic Health  
14  
15 Evaluation II score will be used to assess the severity of the disease within 24 h after  
16  
17 EICU admission. Source of infection, use of mechanical ventilation before/after AKI  
18  
19 development, and medication for treatment were also collected. Each patient will be  
20  
21 followed for at least 7 consecutive days using routine haematology and biochemistry  
22  
23 testing for complete blood count, haemoglobin, arterial blood gas, arteriovenous oxygen  
24  
25 difference, pro-brain natriuretic peptide, plasma protein, C-reactive protein, SCr, and  
26  
27 estimated glomerular filtration rate. The frequency of laboratory tests in patients with  
28  
29 stable vital signs is once a day, however, for septic shock patients, laboratory tests may  
30  
31 be performed every 8 hours.  
32  
33  
34  
35  
36  
37  
38  
39

40 Work sheets will also be maintained to record the patients' vital signs (temperature, heart  
41  
42 rate, respiration, blood pressure, mean arterial pressure, central venous pressure, SpO<sub>2</sub>),  
43  
44 neurological signs (Glasgow coma score), medication, intake, and output. The dosage and  
45  
46 frequency will be recorded for vasoactive drugs in cases of shock. Conventional  
47  
48 ultrasonography and CEUS scans will be performed on days 0, 1, 3, and 7 after EICU  
49  
50 admission, for septic shock patients, we performed CEUS before fluid resuscitation, and  
51  
52 then we would re-evaluate renal microvascular alterations by the use of CEUS with  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 resuscitation targeted at normalization of blood pressure. All imaging will be  
5  
6 performed by highly experienced EICU physicians with >10 years of experience  
7  
8 performing bedside ultrasonography. Survival outcomes in the EICU, at 1 month, at 3  
9  
10 months, at 1 year, and at 2 years after discharge will be determined using outpatient visits  
11  
12 or telephone interviews.  
13  
14  
15

### 16 17 **Conventional ultrasonography**

18  
19 Conventional two-dimensional ultrasonography scans will be performed using a 3.5–5  
20  
21 MHz convex ultrasound probe (Mindray M9, China) to evaluate the size, morphology,  
22  
23 and macrovascular supply of the kidneys, which will be consistently imaged in the  
24  
25 longitudinal plane. Colour Doppler flow imaging will be used to evaluate the peak  
26  
27 systolic velocity, resistance index, and end diastolic velocities of the segmental artery,  
28  
29 interlobar artery, and arcuate artery. Cardiac and lung functions will be assessed using  
30  
31 bedside echocardiography and lung ultrasonography[15 16] , with data including the left  
32  
33 ventricular ejection fraction, E-point to septal separation , and the respiratory variation of  
34  
35 the inferior vena cava diameter.  
36  
37  
38  
39  
40  
41  
42

### 43 **Performance of CEUS**

44  
45 The CEUS will be performed immediately after the long-axis view of the kidney has been  
46  
47 obtained using conventional ultrasonography. SonoVue® is a commercial ultrasound  
48  
49 contrast agent (Bracco, Milan, Italy) that will be administered intravascularly with a  
50  
51 bolus of 1–2.4 mL based on the patient's weight, height, and age. The bolus will then be  
52  
53 followed by a 10-mL injection of physiological saline via a peripheral antecubital vein.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 The timer and imaging recorder will be activated simultaneously with the contrast agent  
5  
6 injection, and the procedure will last for a total of 4–6 min. A lower mechanical index  
7  
8 will be applied, although the mechanical parameters will be standardized for all patients.

9  
10  
11 We will manually define three circular regions of interest (diameters of 1.5–2.0 cm) at the  
12  
13 renal cortex and medulla, which are at the same approximate location, to analyse renal  
14  
15 microcirculation perfusion. Care will be taken to avoid nearby vessels (Figure 1).  
16  
17

18  
19 The two phase terms will be the cortical phases (from 10–15 s after injection until 30–45  
20  
21 s) and the medullary phases (approximately 30–45 s after injection until the microbubble  
22  
23 echoes disappear completely).[17] The renal cortex may become enhanced earlier than  
24  
25 the renal medulla, and a second contrast agent injection will be performed at an interval  
26  
27 of approximately 15 min if necessary. In that scenario, the microbubbles should be  
28  
29 destroyed during the interval using the highest acoustic power setting. Images and video  
30  
31 clips from the CEUS will be digitally stored for subsequent quantitative analysis.  
32  
33  
34

35  
36 The time-intensity curves will be created using software to analyse blood volume and  
37  
38 velocity based on the following parameters: baseline intensity (intensity before the  
39  
40 contrast agent arrives in the microcirculation), arrival time (the time when the contrast  
41  
42 agent appears), time-to-peak (the time to the maximum contrast intensity), peak intensity  
43  
44 (the maximum contrast intensity value), ascending slope, descending time/2, descending  
45  
46 slope, and area under the curve (Figure 2).[18]  
47  
48  
49  
50  
51

## 52 53 **Statistical analysis**

54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 All statistical analyses will be performed using SPSS software (version 17.0; SPSS Inc.,  
5  
6 Chicago, IL) and MedCalc® software (Mariakerke, Belgium). Differences will be  
7  
8 considered statistically significant at two-tailed *P*-values of <0.05. Categorical data will  
9  
10 be compared using the chi-square test. Continuous data will be reported as mean ±  
11  
12 standard deviation and compared using Student's *t* test.[19] Variables that are significant  
13  
14 in the univariate analyses will be included in multivariate logistic regression analysis.[20]  
15  
16  
17 A receiver operating characteristic curve will also be created to examine the ability of  
18  
19 CEUS to predict AKI based on the sensitivity, specificity, accuracy, positive predictive,  
20  
21 and negative predictive values.  
22  
23  
24  
25

## 26 27 **DISCUSSION**

28  
29  
30 SA-AKI is common among critically ill patients and is an important cause of ICU  
31  
32 admission with significant morbidity and mortality. The incidence of SA-AKI in the ICU  
33  
34 is approximately 55–60% and the mortality rate is approximately 27%.[21] Although  
35  
36 SA-AKI is manageable, progression to chronic renal failure can lead to tremendous  
37  
38 psychological and economic burdens on the patient. Thus, many studies have explored  
39  
40 biomarkers for predicting SA-AKI development among critically ill patients, although  
41  
42 those studies have revealed limited predictive values.[22-24]  
43  
44  
45  
46

47  
48 To the best of our knowledge, SA-AKI is still a common condition that lacks an effective  
49  
50 therapy. Logically, a better understanding of the pathophysiology of SA-AKI is critical  
51  
52 important, which can help to develop effective measures to improve the prognosis,  
53  
54 disease management and long-term follow-up.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 The underlying pathophysiology of SA-AKI is complex and multifactorial, growing  
5  
6 evidences suggest that patients with SA-AKI exhibit altered blood flow to the  
7  
8 macrovascular and microvasculature beds. The global renal ischemia, cellular damage,  
9  
10 and acute tubular necrosis [25-27] were once regarded as the three main causes leading to  
11  
12 the change of the renal macrocirculation in SA-AKI. However, some new study  
13  
14 demonstrated that , in the first 48 hours, pathophysiological alterations of SA-AKI may  
15  
16 be functional rather than structural in nature[28], and potentially reversible.[29]  
17  
18  
19 Furthermore, histological assessment of postmortem kidneys from patients dying of  
20  
21 SA-AKI showed an absence of acute tubular necrosis and tubular cell apoptosis.[30 31]  
22  
23  
24 Therefore, it is crucially important to identify the SA-AKI as early as possible within 48  
25  
26 hours.  
27  
28  
29

30  
31  
32 Recently , some researchs indicated that renal microvascular abnormalities play a central  
33  
34 role in SA-AKI[32]. Someone have confirmed that the onset ischemia tissue in the early  
35  
36 stage of SA-AKI was the medulla of the kidney ,which may change several hours prior to  
37  
38 development of oliguria and increased plasma creatinine. [33 34] Then, changes in  
39  
40 cortical renal perfusion were heterogeneous from non-AKI to evolving SA-AKI ,even at  
41  
42 different stages of SA-AKI development. In large animal models, including pigs and  
43  
44 sheep, SA-AKI was considered to be associated with a hyperdynamic circulation in  
45  
46 which the renal cortical tissue was highly perfused and oxygenated.[35 36]However,  
47  
48 some reports suggested that the decrease in cortical renal perfusion was associated with  
49  
50 severe AKI occurrence.[33]  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 In agreement with these studies, our study expected to explore changes in the renal cortex  
5  
6 and medullary microcirculation with septic patients during their first 7 days of care. In  
7  
8 this study, we would separate patients into four categories (no SA-AKI, stage 1, stage 2,  
9  
10 stage 3 SA- AKI) after 7 consecutive days of monitoring , and then try to find the  
11  
12 correlation between the change of microcirculation in kidney and the occurrence or  
13  
14 progression of SA-AKI .  
15  
16  
17  
18

19 In fact, similar studies have been carried out in which the perfusion of the renal cortex is  
20  
21 significantly reduced in patients with severe AKI occurrence (KDIGO stages 2 or 3) in  
22  
23 course of sepsis shock by using CEUS.[37] However, they only measured cortical  
24  
25 perfusion in patients with septic shock while medullary perfusion was not mentioned.  
26  
27 Because renal perfusion patterns are heterogeneous in patients with sepsis, and  
28  
29 thus, CEUS may be useful for providing continuous real-time monitoring of the capillary  
30  
31 microcirculation, and this ability is enhanced with the use of ultrasound contrast  
32  
33 agents.[38] SonoVue® is a second-generation contrast agent that is composed of sulphur  
34  
35 hexafluoride-filled microbubbles (2–10 µm), and is considered an ideal intravascular  
36  
37 tracer that facilitates more sensitive, accurate, and non-invasive evaluation of capillary  
38  
39 perfusion. Furthermore, sulphur hexafluoride is not nephrotoxic [38] and can be  
40  
41 completely eliminated via the lungs within a few minutes after its injection, which is  
42  
43 unlike the traditional nephrotoxic contrast agents that are used during computed  
44  
45 tomography and magnetic resonance imaging. Finally, the phospholipid shell of the  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 SonoVue® microbubbles is very compliant and is not destroyed at a low mechanical  
5  
6 index ( $<0.16$ ) during CEUS.[38]  
7

8  
9 A map of the kidney microvasculature can be provided with high temporal and spatial  
10  
11 resolution using CEUS,[10] and three-dimensional CEUS can provide detailed  
12  
13 information regarding abnormal blood flow based on perfusion volumes or lack thereof.  
14  
15 For example, Dong et al. have indicated that CEUS might provide clinically useful tissue  
16  
17 perfusion data for the early diagnosis of diabetic nephropathies using quantitative  
18  
19 evaluation of renal cortex perfusion.[39] Furthermore, CEUS is widely used in the  
20  
21 dynamic assessment of postoperative complications, such as tissue hypoperfusion, vessel  
22  
23 stenosis, dilatation or embolization, active bleeding, and the development of  
24  
25 inflammation or infection.[40 41] Tumour microvasculature and angiogenesis can also be  
26  
27 assessed using CEUS,[42] and Fischer et al. have reported that CEUS was superior to  
28  
29 traditional ultrasonography for identifying acute rejection after renal transplantation.[43]  
30  
31 Wang et al. have also recently evaluated CEUS for monitoring renal microcirculation  
32  
33 after kidney transplantation,[44] and suggested that peak systolic velocity, end diastolic  
34  
35 velocity, resistance index, and pulsatility index from colour Doppler ultrasound scans  
36  
37 could not differentiate between patients with normal and abnormal SCr levels. However,  
38  
39 CEUS in that study revealed a significant inter-group difference in the renal parenchymal  
40  
41 microcirculation in terms of the slope rate of the cortical ascending curve , the medullary  
42  
43 ascending curve , and the peak intensity. Nevertheless, there are limited reports regarding  
44  
45 the application of CEUS among patients with SA-AKI, and our present study revealed  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 that CEUS could be combined with the SonoVue® agent, specific regions of interest, and  
5  
6 the time-intensity curve to dynamically analyse renal microcirculation perfusion. This  
7  
8 information may be useful for predicting the risk of developing SA-AKI, which could  
9  
10 facilitate early and effective treatment that may improve the patient's prognosis.  
11  
12

13  
14 The use of CEUS for evaluating renal microcirculation has several important advantages,  
15  
16 such as being a relatively uncomplicated procedure that can be performed at the patient's  
17  
18 bedside during emergency management. In addition, there is no exposure to radiation or  
19  
20 risk of nephrotoxicity, which would impair renal perfusion and increase the risk of  
21  
22 nephrogenic systemic fibrosis. Moreover, CEUS is safe for patients of all ages, including  
23  
24 children, critically ill patients, and older individuals. The Food and Drug Administration  
25  
26 has approved CEUS for use in paediatric patients, and ongoing clinical studies are  
27  
28 evaluating the safety of the SonoVue® agent in this setting.[45] Finally, CEUS  
29  
30 overcomes the shortcomings of conventional B-mode sonography, which cannot detect  
31  
32 small blood vessels and has poor sensitivity at low velocities and amplitudes.  
33  
34  
35  
36  
37  
38  
39

40 The present study also has several limitations that will need to be considered. For  
41  
42 example, individual-level differences may limit the generalizability of the results, and  
43  
44 hypothermia is known to alter blood flow and ultimately the distribution of the contrast  
45  
46 agent.[46] However, there were not enough evidences to determine whether heart rate,  
47  
48 blood pressure, pulmonary artery pressure, or cardiac chamber pressure affect  
49  
50 enhancement after the contrast agent injection especially for critically ill patients. In  
51  
52 addition, inter-operator variability may affect the findings, which we considered a  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 subjective error. Third, there is a fairly long interval between the CEUS examinations, and  
5  
6 thus some important microcirculatory alteration nodes may not be detected promptly..  
7

8  
9 In conclusion, the present study aims to use CEUS to evaluate renal microcirculation  
10  
11 changes in septic patients and attempt to find out the correlation between the change of  
12  
13 microcirculation and the occurrence or progression of SA-AKI.  
14  
15

## 16 REFERENCES

- 17 1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus  
18 Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama* 2016;**315**:801-10.
- 19 2. Fleischmann C, Scherag A, Adhikari NKJ, et al. Assessment of Global Incidence and  
20 Mortality of Hospital-treated Sepsis. *American journal of respiratory and*  
21 *critical care medicine* 2016;**193**:259-72.
- 22 3. Section 2: AKI Definition. *Kidney international supplements* 2012;**2**(1):19-36 .
- 23 4. Zhang Z. Biomarkers, diagnosis and management of sepsis-induced acute kidney  
24 injury: a narrative review. *Heart, lung and vessels* 2015;**7**:64-73.
- 25 5. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a  
26 multinational, multicenter study. *Jama* 2005;**294**:813-8.
- 27 6. Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney  
28 disease as interconnected syndromes. *The New England journal of medicine*  
29 2014;**371**:58-66.
- 30 7. Greenberg JH, Coca S, Parikh CR. Long-term risk of chronic kidney disease and  
31 mortality in children after acute kidney injury: a systematic review. *BMC*  
32 *nephrology* 2014;**15**.10.1186/1471-2369-15-184[published Online First:  
33 Epub Date]].
- 34 8. Odutayo A, Wong CX, Farkouh M, et al. AKI and Long-Term Risk for  
35 Cardiovascular Events and Mortality. *J Am Soc Nephrol* 2017;**28**:377-87.
- 36 9. Zhang Z, Hong Y, Liu N, et al. Diagnostic accuracy of contrast enhanced ultrasound  
37 in patients with blunt abdominal trauma presenting to the emergency  
38 department: a systematic review and meta-analysis. *Scientific reports*  
39 2017;**7**:4446.
- 40 10. Harvey CJ, Sidhu PS, Bachmann Nielsen M. Contrast-enhanced ultrasound in  
41 renal transplants: applications and future directions. *Ultraschall in der*  
42 *Medizin* 2013;**34**:319-21.
- 43 11. Fernandez CP, Ripolles T, Martinez MJ, et al. Diagnosis of acute cortical necrosis  
44 in renal transplantation by contrast-enhanced ultrasound: a preliminary  
45 experience. *Ultraschall in der Medizin* 2013;**34**:340-4.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

12. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract* 2012;**120**:c179-84.
13. Sileanu FE, Murugan R, Lucko N, et al. AKI in low-risk versus high-risk patients in intensive care. *Clinical journal of the American Society of Nephrology : CJASN* 2015;**10**:187-96.
14. Liang KV, Sileanu FE, Clermont G, et al. Modality of RRT and Recovery of Kidney Function after AKI in Patients Surviving to Hospital Discharge. *Clinical journal of the American Society of Nephrology : CJASN* 2016;**11**:30-8.
15. Lichtenstein DA. BLUE-protocol and FALLS-protocol: two applications of lung ultrasound in the critically ill. *Chest* 2015;**147**:1659-70.
16. Perera P, Mailhot T, Riley D, et al. The RUSH exam: Rapid Ultrasound in SHock in the evaluation of the critically ill. *Emergency medicine clinics of North America* 2010;**28**:29-56.
17. Harvey CJ, Alsafi A, Kuzmich S, et al. Role of US Contrast Agents in the Assessment of Indeterminate Solid and Cystic Lesions in Native and Transplant Kidneys. *Radiographics : a review publication of the Radiological Society of North America, Inc* 2015;**35**:1419-30.
18. Dietrich CF, Averkiou MA, Correas JM, et al. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. *Ultraschall in der Medizin* 2012;**33**:344-51.
19. Zhang Z. Univariate description and bivariate statistical inference: the first step delving into data. *Annals of translational medicine* 2016;**4**:91.
20. Zhang Z. Model building strategy for logistic regression: purposeful selection. *Annals of translational medicine* 2016;**4**:111.
21. Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive care medicine* 2015;**41**:1411-23.
22. Zhang Z, Lu B, Ni H, et al. Microalbuminuria can predict the development of acute kidney injury in critically ill septic patients. *Journal of nephrology* 2013;**26**:724-30.
23. Zhang Z, Lu B, Sheng X, et al. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. *American journal of kidney diseases : the official journal of the National Kidney Foundation* 2011;**58**:356-65.
24. Zhang Z, Xu X, Fan H, et al. Higher serum chloride concentrations are associated with acute kidney injury in unselected critically ill patients. *BMC nephrology* 2013;**14**:235.
25. Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. *Shock* 2014;**41**:3-11|.
26. Post EH, Kellum JA, Bellomo R, et al. Renal perfusion in sepsis: from macro- to microcirculation. *Kidney international* 2017;**91**:45-60 |.

- 1  
2  
3 27. Schrier RW, Wang W. Acute renal failure and sepsis. *The New England journal of*  
4 *medicine* 2004;**351**:159-69.
- 5  
6 28. Kosaka J, Lankadeva YR, May CN, et al. Histopathology of Septic Acute Kidney  
7 *Injury: A Systematic Review of Experimental Data. Critical care medicine*  
8 *2016*;**44**:e897-903.
- 9  
10 29. May CN, Calzavacca P, Ishikawa K, et al. Novel targets for sepsis-induced kidney  
11 *injury: the glomerular arterioles and the sympathetic nervous system.*  
12 *Experimental physiology* 2012;**97**:1168-77.
- 13  
14 30. Takasu O, Gaut JP, Watanabe E, et al. Mechanisms of cardiac and renal  
15 *dysfunction in patients dying of sepsis. American journal of respiratory and*  
16 *critical care medicine* 2013;**187**:509-17.
- 17  
18 31. Langenberg C, Bagshaw SM, May CN, et al. The histopathology of septic acute  
19 *kidney injury: a systematic review. Critical care* 2008;**12**:R38.
- 20  
21 32. Matejovic M, Ince C, Chawla LS, et al. Renal Hemodynamics in AKI: In Search of  
22 *New Treatment Targets. J Am Soc Nephrol* 2016;**27**:49-58.
- 23  
24 33. Calzavacca P, Evans RG, Bailey M, et al. Cortical and Medullary Tissue Perfusion  
25 *and Oxygenation in Experimental Septic Acute Kidney Injury. Critical care*  
26 *medicine* 2015;**43**:e431-9.
- 27  
28 34. Lankadeva YR, Kosaka J, Evans RG, et al. Urinary Oxygenation as a Surrogate  
29 *Measure of Medullary Oxygenation During Angiotensin II Therapy in Septic*  
30 *Acute Kidney Injury. Critical care medicine* 2018;**46**:e41-e48.
- 31  
32 35. Chvojka J, Sykora R, Krouzecky A, et al. Renal haemodynamic, microcirculatory,  
33 *metabolic and histopathological responses to peritonitis-induced septic*  
34 *shock in pigs. Critical care* 2008;**12**:R164.
- 35  
36 36. Correa TD, Jeger V, Pereira AJ, et al. Angiotensin II in septic shock: effects on  
37 *tissue perfusion, organ function, and mitochondrial respiration in a porcine*  
38 *model of fecal peritonitis. Critical care medicine* 2014;**42**:e550-9.
- 39  
40 37. Harrois A, Grillot N, Figueiredo S, et al. Acute kidney injury is associated with a  
41 *decrease in cortical renal perfusion during septic shock. Critical care*  
42 *2018*;**22**.10.1186/S13054-018-2067-0[*published Online First: Epub Date*].
- 43  
44 38. Greis C. Technical aspects of contrast-enhanced ultrasound (CEUS)  
45 *examinations: tips and tricks. Clinical hemorheology and microcirculation*  
46 *2014*;**58**:89-95.
- 47  
48 39. Dong Y, Wang WP, Lin P, et al. Assessment of renal perfusion with  
49 *contrast-enhanced ultrasound: Preliminary results in early diabetic*  
50 *nephropathies. Clinical hemorheology and microcirculation* 2016;**62**:229-38.
- 51  
52 40. Gocze I, Wohlgemuth WA, Schlitt HJ, et al. Contrast-enhanced ultrasonography  
53 *for bedside imaging in subclinical acute kidney injury. Intensive care*  
54 *medicine* 2014;**40**:431.
- 55  
56 41. Sessa B, Trinci M, Ianniello S, et al. Blunt abdominal trauma: role of  
57 *contrast-enhanced ultrasound (CEUS) in the detection and staging of*  
58  
59

- 1  
2  
3 abdominal traumatic lesions compared to US and CE-MDCT. *La Radiologia*  
4 *medica* 2015;**120**:180-9.
- 5  
6 42. Reimann R, Rubenthaler J, Hristova P, et al. Characterization of histological  
7 subtypes of clear cell renal cell carcinoma using contrast-enhanced  
8 ultrasound (CEUS). *Clinical hemorheology and microcirculation*  
9 2015;**63**:77-87.
- 10  
11 43. Fischer T, Muhler M, Kroncke TJ, et al. Early postoperative ultrasound of kidney  
12 transplants: evaluation of contrast medium dynamics using time-intensity  
13 curves. *RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der*  
14 *Nuklearmedizin* 2004;**176**:472-7.
- 15  
16 44. Wang X, Yu Z, Guo R, et al. Assessment of postoperative perfusion with  
17 contrast-enhanced ultrasonography in kidney transplantation. *International*  
18 *journal of clinical and experimental medicine* 2015;**8**:18399-405.
- 19  
20 45. Rosado E, Riccabona M. Off-Label Use of Ultrasound Contrast Agents for  
21 Intravenous Applications in Children: Analysis of the Existing Literature.  
22 *Journal of ultrasound in medicine : official journal of the American Institute*  
23 *of Ultrasound in Medicine* 2016;**35**:487-96.
- 24  
25 46. Hyvelin JM, Tardy I, Arbogast C, et al. Use of ultrasound contrast agent  
26 microbubbles in preclinical research: recommendations for small animal  
27 imaging. *Investigative radiology* 2013;**48**:570-83.
- 28  
29  
30  
31  
32

### 33 **FIGURE LEGENDS**

34  
35 **Figure 1:** A color-coded map with circular regions of interest (ROIs) at the renal cortex  
36 and medulla.  
37

38  
39 **Figure 2:** A color-coded graph comparing the quantitative contrast-enhanced ultrasound  
40 parameters between the groups with and without acute kidney injury. GOF: goodness of fit, BI:  
41 baseline intensity, AT: arrival time, TTP: time-to-peak, PI: peak intensity, AS: ascending  
42 slope, DT/2: descending time/2, DS: descending slope, AUC: area under the curve.  
43  
44  
45  
46  
47  
48  
49

### 50 **Footnotes**

1  
2  
3  
4 **Contributors:** All listed authors have participated in the study, and have  
5  
6 reviewed and approved the submitted manuscript. LN, ZZH, and HYC designed this  
7  
8 study. DJR, LL, QX, and JQC drafted and submitted the report. CHB, ZH, and LB  
9  
10 revised the report.  
11  
12

13  
14 **Funding:** The study was supported by the Zhejiang Provincial Natural Science  
15  
16 Foundation of China (LGF18H150005) and Scientific research project of Zhejiang  
17  
18 Education Commission (Y201737841).  
19  
20

21  
22 **Competing interests:** None declared.  
23

24 **Ethics approval:** The study protocol was approved by the ethics committee of Sir Run  
25  
26 Run Shaw Hospital (Zhejiang University Medical College , registration number:  
27  
28 2016C91401).  
29

30 **Provenance and peer review:** Not commissioned, externally peer reviewed.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: A color-coded map with circular regions of interest (ROIs) at the renal cortex and medulla.

106x73mm (300 x 300 DPI)




Figure 2: A color-coded graph comparing the quantitative contrast-enhanced ultrasound parameters between the groups with and without acute kidney injury. GOF: goodness of fit, BI: baseline intensity, AT: arrival time, TTP: time-to-peak, PI: peak intensity, AS: ascending slope, DT/2: descending time/2, DS: descending slope, AUC: area under the curve.

106x73mm (300 x 300 DPI)

# BMJ Open

## A protocol for a prospective observational study on the association of variables obtained by contrast-enhanced ultrasonography and sepsis-associated acute kidney injury

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023981.R2
Article Type:	Protocol
Date Submitted by the Author:	05-Mar-2019
Complete List of Authors:	liu, ning; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhang, Zhongheng; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Hong, Yucai; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, emergency medicine Li, Bing; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Cai, Huabo; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Zhao, Hui; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Dai, Junru; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Liu, Lian; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Qian, Xin; Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China Jin, Qicheng; Department of Ultrasound Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Renal medicine
Keywords:	sepsis, acute kidney injury, prediction, contrast-enhanced ultrasonography

SCHOLARONE™  
Manuscripts

# A protocol for a prospective observational study on the association of variables obtained by contrast-enhanced ultrasonography and sepsis-associated acute kidney injury

Ning Liu,<sup>1</sup> Zhongheng Zhang, \*<sup>1</sup> Yucai Hong, <sup>1</sup> Bing Li,<sup>1</sup> Huabo Cai,<sup>1</sup> Hui Zhao,<sup>1</sup> Junru Dai,<sup>1</sup> Lian Liu,<sup>1</sup> Xin Qian,<sup>1</sup> Qicheng Jin<sup>2</sup>

1. Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

2. Department of Ultrasound Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

\*Corresponding author: Zhongheng Zhang, Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, China; Tel.: (0571) 88006810; Email: zh\_zhang1984@zju.edu.cn

## ABSTRACT

**Introduction:** Sepsis commonly results in acute kidney injury (AKI), whereas about 50% of AKI cases are due to sepsis. Sepsis-associated acute kidney injury (SA-AKI) increases morbidity and mortality especially among critically ill patients. This study aims to monitor renal microcirculation perfusion during sepsis using contrast-enhanced ultrasonography (CEUS), and to explore whether CEUS is useful for predicting the development of SA-AKI.

**Methods and analysis:** This prospective observational study will enroll patients who were diagnosed with sepsis-3 definition. The total of septic or septic shock patients were stratified into AKI (including stage 1, 2, and 3) and non-AKI groups according to Kidney Disease Improving Global Outcomes (KDIGO) criteria on days 0, 1, 2, and 7 after admission to the emergency intensive care unit, meanwhile, the CEUS technique will be performed to monitor renal microcirculation perfusion. A multivariable model including all CEUS variables were expected to create for predicting the development of AKI during sepsis. Ultrasonography results,

1  
2  
3 demographic information, therapeutic interventions, survival outcomes, laboratory and other  
4 clinical datas will also be collected for further analysis.  
5  
6

7  
8 **Ethics and dissemination:** The study protocol was approved on 2 August 2017 by the Ethics  
9 Committee of Sir Run Run Shaw Hospital (Zhejiang University Medical College) ,(approval  
10 numbe: 2016C91401). The results will be published in a peer-reviewed journal and shared with  
11 the worldwide medical community within 2 years after the start of the recruitment.  
12  
13  
14  
15

16  
17 **Trial registration:** ISRCTN 14728986; Pre-results  
18

### 19 **Strengths and limitations of this study:**

20  
21 1. In this study, we expected to monitor changes of the renal microcirculation including cortex  
22 and medullary by CEUS among patients with sepsis in their first 7 days and try to certify the  
23 possibility of redistribution of intra-renal microcirculatory blood flow.  
24  
25  
26  
27

28 2. The CEUS is an uncomplicated and non-nephrotoxic procedure with the rare occurrence of  
29 serious side effects and anaphylactic reactions , which should be especially considered in the  
30 intensive care unit.  
31  
32  
33  
34

35 3. Limited patients enrolled in the group which will make the available datas inconclusive.  
36  
37

### 38 **INTRODUCTION**

39 Sepsis is a syndrome that involves an over-activated systemic inflammatory response to  
40 infection. This condition can lead to multiple organ dysfunction, with the kidneys being a  
41 commonly involved organ.[1 2] Acute kidney injury is characterized by the loss of kidney  
42 function with an increase in serum creatinine and/ or a decrease in urinary output.[3] Sepsis is  
43 one of the most common causes of AKI, accounting for 50% of all cases, and up to 60% of  
44 patients with sepsis have AKI.[4 5] SA-AKI is defined by the simultaneous presence of the  
45 recent Sepsis-3 consensus criteria for sepsis[1] and the Kidney Disease Improving Global  
46 Outcomes (KDIGO) consensus criteria for AKI.[6]  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Current studies indicated that SA-AKI and chronic kidney disease are closely-related rather than  
4 independent conditions, and even a mild or short-term of SA-AKI have a tendency to develop  
5 into chronic and end-stage kidney disease in the near future.[7 8] Thus, early prediction and  
6 recognition of SA-AKI are important steps in the early and effective initiation of proper therapy,  
7 which can prevent further complications and multiple organ dysfunction. Former researches  
8 regarding the pathogenesis of SA-AKI mainly focused on the renal macrocirculation resulting  
9 from global renal ischemia, cellular damage, and acute tubular necrosis.[9-11] However, recent  
10 advances have enhanced our knowledge of the pathobiology of SA-AKI. [12-14] In SA-AKI,  
11 microvascular dysfunction is characterized by a wide heterogeneity in blood flow distribution  
12 across the renal tissues and the same microcirculatory derangements have been detected in the  
13 renal capillaries.[15] Therefore, early detection of renal microcirculation dysfunction during and  
14 after sepsis may facilitate subsequent treatment and prognostic prediction.

15 Contrast-enhanced ultrasonography which is a relatively novel modality with microbubble-based  
16 contrast agents have provided real-time anatomic and functional information in the study of  
17 microvascular flow in patients with SA-AKI without ionizing radiation.[16] Currently, CEUS has  
18 become widely used in the emergency department for evaluating cases of abdominal blunt  
19 trauma,[17]however, the use of CEUS in SA-AK cases is limited and it remains unclear whether  
20 it can provide useful information for predicting the development.

21 Therefore, as a primary objective, the present study aims to use CEUS at an emergency  
22 intensive care unit to monitor renal microcirculation perfusion (including cortex and  
23 medullary) in the first 7 days of being diagnosed with sepsis. Then, we expected to create a  
24 multivariable model including all CEUS parameters to predict the development of SA- AKI.

## 25 **METHODS AND ANALYSIS**

## Study design

This prospective observational study will enroll patients with sepsis and septic shock who are treated at an interdisciplinary EICU (Sir Run Run Shaw Hospital, Zhejiang University) between August 11, 2017 and September 30, 2019. All conscious patients will be educated regarding the study's protocol and purposes. If patients were diagnosed with septic shock or even were ventilated and sedated, informed consent will be written by their family members, instead.

## Cohort descriptions and definitions

We plan to recruit 200 patients. Patients with sepsis and septic shock will be screened for eligibility if they are >18 years old. The exclusion criteria are 1) an expected stay of <24 h, 2) the presence of end-stage kidney disease or long-term haemodialysis, 3) critically ill patients who have started renal replacement therapy caused by SA-AKI before EICU admission, 4) a history of kidney transplantation, and 5) Urinary tract obstruction.

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. For clinical operationalization, organ dysfunction can be represented by an acute change of  $\geq 2$  points in the total Sequential Organ Failure Assessment score. Septic shock is defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure of  $\geq 65$  mmHg and serum lactate levels of  $> 2$  mmol/L (18 mg/dL) despite adequate resuscitation volume (Table 1).<sup>[1]</sup>

**Table 1** Sepsis-3 definitions and quick SOFA (qSOFA) criteria

Sepsis-3 definitions
Sepsis—Life threatening organ dysfunction caused by a dysregulated host response to infection
Septic shock—sepsis with a requirement for vasoactive therapy to maintain mean arterial pressure $\geq 65$ mmHg and lactate elevation to $> 2$ mmol/L despite adequate volume resuscitation

---

 qSOFA criteria

- Respiratory rate  $\geq 22$  breaths per minute
- Altered mentation
- Systolic blood pressure  $\leq 100$  mmHg

---

 qSOFA, quick SOFA; SOFA: Sequential [Sepsis-related] Organ Failure Assessment.

In order to identify patients with SA-AKI as early as possible, we could apply the Kidney Disease Improving Global Outcomes (KDIGO) guidelines to our subjects, which stratifies SA-AKI in three different stages according to changes in creatinine and urine output (Table 2)[6]. Baseline creatinine value ( $\mu\text{mol/L}$ ) was either registered from 6 months previous clinical files or estimated, when data was not available from clinical records, by solving the Modification of Diet in Renal Disease (MDRD) equation assuming a glomerular filtration rate of  $75 \text{ ml/min/1.73 m}^2$ . [18 19]

**Table 2** Staging of Sepsis-Associated Acute Kidney Injury (SA-AKI)

Stage	Serum Creatinine	Urine Output
1	1.5 - 1.9 times baseline OR $\geq 0.3 \text{ mg/dl}$ ( $\geq 26.5 \text{ mmol/l}$ ) increase	$< 0.5 \text{ ml/kg/h}$ for 6 - 12 hours
2	2.0 - 2.9 times baseline	$< 0.5 \text{ ml/kg/h}$ for $\geq 12$ hours
3	3.0 times baseline OR Increase in serum creatinine to $\geq 4.0 \text{ mg/dl}$ ( $\geq 353.6 \text{ mmol/l}$ ) OR Initiation of renal replacement therapy OR, In patients $< 18$ years, decrease in eGFR to $< 35 \text{ ml/min per } 1.73 \text{ m}^2$	$< 0.3 \text{ ml/kg/h}$ for $\geq 24$ hours OR Anuria for $\geq 12$ hours

eGFR: estimated glomerular filtration rate

### Patient and Public Involvement

1  
2  
3 No patients were involved in developing plans for design or implementation of the study, nor  
4  
5 were they involved in setting the research question or the outcome measures. No patients were  
6  
7 requested to advise on interpretation or writing up of results. There are no plans to disseminate  
8  
9 the results of the research to study participants or the relevant patient community.  
10  
11

## 12 **Data collection**

13  
14 Demographic information and chronic disease history will be collected as baseline characteristics  
15  
16 during the hospitalization. The Acute Physiology And Chronic Health Evaluation II score will be  
17  
18 used to assess the severity of the disease within 24 h after EICU admission. Source of infection,  
19  
20 use of mechanical ventilation before/after AKI development, and therapeutic interventions (the  
21  
22 volume and kind of fluid resuscitation , vasopressor therapy, antimicrobial therapy, renal  
23  
24 replacement therapy) will be also collected. Each patient will be followed for at least 7  
25  
26 consecutive days using routine haematology and biochemistry testing for complete blood count,  
27  
28 haemoglobin, arterial blood gas, arteriovenous oxygen difference, pro-brain natriuretic peptide,  
29  
30 plasma protein, C-reactive protein, SCr, and estimated glomerular filtration rate. The frequency  
31  
32 of laboratory tests in patients with stable vital signs is once a day, however, for septic shock  
33  
34 patients, laboratory tests may be performed every 8 hours.  
35  
36  
37

38  
39 Work sheets will also be maintained to record the patients' vital signs (temperature, heart rate,  
40  
41 respiration, blood pressure, mean arterial pressure, central venous pressure, SpO<sub>2</sub>), neurological  
42  
43 signs (Glasgow coma score), medication, intake, and output. The dosage and frequency will be  
44  
45 recorded for vasoactive drugs in cases of shock. Conventional B-mode ultrasonography and  
46  
47 CEUS scans will be performed on days 0, 1, 2, and 7 after EICU admission. For septic shock  
48  
49 patients, we performed CEUS before fluid resuscitation, and then we would re-evaluate renal  
50  
51 microvascular alterations by the use of CEUS with resuscitation targeted at normalization of  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 blood pressure(mean arterial pressure of CE). All ultrasonography examinations were  
4 performed by the collaboration of experienced EICU physicians and ultrasonologist. Perfusion  
5 time intensity curve (TIC) analysis [20] was performed using the integrated computer  
6 workstation (LOGIQ E9, GE). Clinical and biochemical data were retrieved from a clinical  
7 database. Data collection was permitted by the ethical review committee of the Sir Run Run  
8 Shaw Hospital (Zhejiang University Medical College). Survival outcomes in the EICU, at 1  
9 month, at 3 months, at 1 year, and at 2 years after discharge will be determined using outpatient  
10 visits or telephone interviews.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

### 21 **Conventional B-mode ultrasonography**

22  
23 Conventional B-mode ultrasonography scans will be performed using a 3.5–5 MHz convex  
24 probe (Mindray M9, China) to evaluate the size, morphology, and macrovascular supply of the  
25 kidneys, which will be consistently imaged in the longitudinal plane. Colour Doppler flow  
26 imaging will be used to evaluate the peak systolic velocity, resistance index and end diastolic  
27 velocities of the segmental artery, interlobar artery and arcuate artery. Cardiac and lung functions  
28 will be assessed using bedside echocardiography and lung ultrasonography ,[21 22] with data  
29 including the left ventricular ejection fraction, E-point to septal separation, and the respiratory  
30 variation of the inferior vena cava diameter.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Performance of CEUS**

43  
44 The CEUS will be performed immediately after the long-axis view of the kidney has been  
45 obtained using conventional B-mode ultrasonography. SonoVue® is a commercial ultrasound  
46 contrast agent (Bracco, Milan, Italy) that will be administered intravascularly with a bolus of 1–  
47 2.4 mL based on the patient's weight, height, and age. The bolus will then be followed by a 10-  
48 mL injection of physiological saline via a peripheral antecubital vein. The timer and imaging  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 recorder will be activated simultaneously with the contrast agent injection, and the procedure  
4  
5 will last for a total of 4–6 min. A lower mechanical index will be applied, although the  
6  
7 mechanical parameters will be standardized for all patients. We will manually define three  
8  
9 circular regions of interest (diameters of 1.5–2.0 cm) at the renal cortex and medulla, which are  
10  
11 at the same approximate location, to analyse renal microcirculation perfusion. Care will be taken  
12  
13 to avoid nearby vessels (Figure 1). A second contrast agent injection will be performed at an  
14  
15 interval of approximately 15 min if necessary. Images and video clips from the CEUS will be  
16  
17 digitally stored for subsequent quantitative analysis.  
18  
19

20  
21 The time-intensity curves will be created using software to analyse blood volume and velocity  
22  
23 based on the following parameters: baseline intensity (intensity before the contrast agent arrives  
24  
25 in the microcirculation), arrival time (the time when the contrast agent appears), time-to-peak  
26  
27 (the time to the maximum contrast intensity), peak intensity (the maximum contrast intensity  
28  
29 value), ascending slope, descending time/2, descending slope, and area under the curve (Figure  
30  
31 2).[23]  
32  
33

### 34 35 **Statistical analysis**

36  
37 All statistical analyses will be performed using SPSS software (version 17.0; SPSS Inc.,  
38  
39 Chicago, IL) and MedCalc® software (Mariakerke, Belgium). Differences will be considered  
40  
41 statistically significant at two-tailed *P*-values of <0.05. Categorical data will be compared using  
42  
43 the chi-square test. Continuous data will be reported as mean ± standard deviation and compared  
44  
45 using Student's *t* test.[24] Variables that are significantly different between AKI and non-AKI  
46  
47 groups in the univariate analyses will be included in multivariate logistic regression analysis.[25]  
48  
49 All CEUS parameters that are statistically significant in univariate analysis will be included in a  
50  
51 multivariable regression model to establish a combined score for the prediction of SA-AKI. [26]  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 A receiver operating characteristic curve will also be created to examine the diagnostic  
4 performance of CEUS (a multivariable model including all CEUS parameters) to predict AKI.  
5  
6 Other diagnostic statistics such as the sensitivity, specificity, accuracy, positive predictive, and  
7  
8 negative predictive values will be reported for the model.  
9  
10

## 11 **DISCUSSION**

12  
13 SA-AKI is common among critically ill patients and is an important cause of ICU admission  
14 with significant morbidity and mortality. The incidence of SA-AKI in the ICU is approximately  
15 55–60% and the mortality rate is approximately 27%. [27] Volume resuscitation, vasopressor  
16 therapy, antimicrobial therapy, and renal replacement therapy remain the mainstays of the  
17 management for SA-AKI in the ICU. [28] Although SA-AKI is manageable, progression to  
18 chronic renal failure can lead to tremendous psychological and economic burdens on the patient.  
19 Thus, a better understanding of the pathophysiology of SA-AKI is essential in order to improve  
20 the prognosis, disease management and long-term follow-up.  
21  
22

23  
24 The underlying pathophysiology of SA-AKI is complex and multifactorial. Evidences suggested  
25 that the global renal ischemia, cellular damage, and acute tubular necrosis [9-11] were once  
26 regarded as the three main causes leading to the change of the renal macrocirculation in SA-AKI.  
27 At present, a growing body of experimental and clinical evidence now shows that, at least in the  
28 early phase of SA-AKI, renal blood flow is normal or even increased. [14 29] Some new study  
29 demonstrated that, in the first 48 hours, pathophysiological alterations of SA-AKI may be  
30 functional rather than structural in nature [30], and potentially reversible. [31] Therefore, it is  
31 crucially important to identify the SA-AKI as early as possible within 48 hours.  
32

33  
34 To the best of our knowledge, the levels of serum creatinine and blood urea nitrogen are the  
35 classical index to evaluate kidney function, but with much higher delayed diagnosis and missed  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 diagnosis rate.[32]Currently, there are still no diagnostic tools for the earlier detection of the SA-  
4 AKI development, although some studies have revealed limited predictive values.[33-35]

5  
6  
7 [30][31][36 37]Recently, a major researchs indicated that renal microvascular abnormalities play  
8 a central role in SA-AKI.[36-39] Disturbances in microcirculatory oxygen delivery may include  
9 both decreased flow and diffusion limitation in the setting of organ edema and  
10 inflammation.[40]The microcirculatory derangements such as capillary plugging and micro-  
11 thrombi have been detected in the renal capillaries in animal models of sepsis-associated acute  
12 kidney injury.[41 42]

13  
14  
15 Previously, CEUS measurement as a diagnostic tool in monitoring renal microcirculatory  
16 perfusion have shown promising results, however, most of them provided information regarding  
17 cortical perfusion.[43-46] Most recently, someone have confirmed that the onset ischemia tissue  
18 in the early stage of SA-AKI was the medulla of the kidney which may change several hours  
19 prior to development of oliguria and increased plasma creatinine. [47 48] Medullary hypoxia due  
20 to intrarenal blood flow redistribution may be one of the factors causing AKI in sepsis.[47]

21  
22  
23 Another study, in an experimental model in mice subjected to ischemia-reperfusion injury (IRI)  
24 demonstrated that CEUS was able to monitor changes in renal microvascular perfusion in space  
25 and time. They reported that the outer medullary perfusion decreased disproportionately to the  
26 reduction in the cortical and inner medullary perfusion after ischemia.[49] The outer medulla  
27 appears to be particularly sensitive to development of hypoxia, because of its poor blood supply  
28 and the large amount of reabsorptive work performed in the proximal tubules and thick  
29 ascending limbs of the loop of Henle.[50]

30  
31  
32 In line with these studies, our study expected to monitor changes in the renal cortical and  
33 medullary microcirculation among septic patients on days 0, 1, 2, and 7 after admission to the  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 emergency intensive care unit. At the same time, we would separate patients into four categories  
4  
5 (no SA-AKI, stage 1, stage 2, stage 3 SA- AKI) according to the consensus criteria for sepsis and  
6  
7 AKI, and then try to find the correlation between the change of microcirculation in kidney and  
8  
9 the development of SA-AKI.  
10

11  
12 The CEUS for evaluating renal microcirculation has several important advantages, such as being  
13  
14 a relatively uncomplicated procedure that can be performed at the patient's bedside during  
15  
16 emergency management. Furthermore, a map of the kidney microvasculature can be provided  
17  
18 with high temporal and spatial resolution.[51] In addition, there is no exposure to radiation or  
19  
20 risk of nephrotoxicity, which would impair renal perfusion and increase the risk of nephrogenic  
21  
22 systemic fibrosis. CEUS can be safe for the critically ill patients and even for the paediatric  
23  
24 patients.[52]  
25

26  
27  
28 The present study also has several limitations that will need to be considered. Firstly, the regions  
29  
30 of interests of the perfusion map were selected subjectively in the kidney and this might very  
31  
32 well represent local micro-heterogeneities.[53] To minimize this parameter, Three ROIs were  
33  
34 drawn for each experimental time point and the results averaged in order to minimize  
35  
36 heterogeneity of measurement. Secondly, this is a prospective observational study conducted in a  
37  
38 10-bed emergency intensive care unit and only 200 patients were to be enrolled in the study ,  
39  
40 therefore, these available datas still remains inconclusive and needs to be further validated by  
41  
42 multicenter cooperation.  
43  
44

45  
46 This narrative protocol aims to use CEUS to monitor the renal microcirculation changes in septic  
47  
48 patients and attempt to find out the correlation between the changes of microcirculation and the  
49  
50 development of SA-AKI.  
51

## 52 53 **FIGURE LEGENDS**

54  
55 **Figure 1:** A color-coded map with circular regions of interest (ROIs) at the renal cortex and medulla.  
56  
57  
58  
59

**Figure 2:** A color-coded graph comparing the quantitative contrast-enhanced ultrasound parameters between the groups with and without acute kidney injury. GOF: goodness of fit, BI: baseline intensity, AT: arrival time, TTP: time-to-peak, PI: peak intensity, AS: ascending slope, DT/2: descending time/2, DS: descending slope, AUC: area under the curve.

## Footnotes

**Contributors:** All listed authors have participated in the study, and have reviewed and approved the submitted manuscript. LN, ZZH, and HYC designed this study. DJR, LL, QX, and JQC drafted and submitted the report. CHB, ZH, and LB revised the report.

**Funding:** The study was supported by the Zhejiang Provincial Natural Science Foundation of China (LGF18H150005) and Scientific research project of Zhejiang Education Commission (Y201737841).

**Competing interests:** None declared.

**Ethics approval:** The study protocol was approved, as described in the text, on 2 August 2017 by the Ethics Committee of Sir Run Run Shaw Hospital (Zhejiang University Medical College, approval number: 2016C91401).

**Provenance and peer review:** Not commissioned, externally peer reviewed.

## REFERENCES

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama* 2016;**315**:801-10.
2. Fleischmann C, Scherag A, Adhikari NKJ, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. *American journal of respiratory and critical care medicine* 2016;**193**:259-72.
3. Section 2: AKI Definition. *Kidney international supplements* 2012;**2**:19-36.
4. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *Jama* 2005;**294**:813-8.
5. Bagshaw SM, Lapinsky S, Dial S, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. *Intensive care medicine* 2009;**35**:871-81.
6. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. *Nephron Clin Pract* 2012;**120**:C179-C84.
7. Greenberg JH, Coca S, Parikh CR. Long-term risk of chronic kidney disease and mortality in children after acute kidney injury: a systematic review. *BMC nephrology* 2014;**15**:184.
8. Odutayo A, Wong CX, Farkouh M, et al. AKI and Long-Term Risk for Cardiovascular Events and Mortality. *J Am Soc Nephrol* 2017;**28**:377-87.

- 1
- 2
- 3
- 4 9. Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney
- 5 injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular
- 6 cell adaptation to injury. *Shock* 2014;**41**:3-11.
- 7
- 8 10. Post EH, Kellum JA, Bellomo R, et al. Renal perfusion in sepsis: from macro- to
- 9 microcirculation. *Kidney international* 2017;**91**:45-60.
- 10
- 11 11. Schrier RW, Wang W. Acute renal failure and sepsis. *The New England journal of*
- 12 *medicine* 2004;**351**:159-69.
- 13
- 14 12. Gomez H, Kellum JA. Sepsis-induced acute kidney injury. *Current opinion in critical care*
- 15 *2016*;**22**:546-53.
- 16
- 17 13. Keir I, Kellum JA. Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and
- 18 treatment recommendations. *Journal of veterinary emergency and critical care*
- 19 *2015*;**25**:200-9.
- 20
- 21 14. Fani F, Regolisti G, Delsante M, et al. Recent advances in the pathogenetic mechanisms
- 22 of sepsis-associated acute kidney injury. *Journal of nephrology* 2018;**31**:351-59.
- 23
- 24 15. Holthoff JH, Wang Z, Seely KA, et al. Resveratrol improves renal microcirculation,
- 25 protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-
- 26 induced acute kidney injury. *Kidney international* 2012;**81**:370-8.
- 27
- 28 16. Mahoney M, Sorace A, Warram J, et al. Volumetric contrast-enhanced ultrasound
- 29 imaging of renal perfusion. *Journal of ultrasound in medicine : official journal of the*
- 30 *American Institute of Ultrasound in Medicine* 2014;**33**:1427-37.
- 31
- 32 17. Zhang Z, Hong Y, Liu N, et al. Diagnostic accuracy of contrast enhanced ultrasound in
- 33 patients with blunt abdominal trauma presenting to the emergency department: a
- 34 systematic review and meta-analysis. *Scientific reports* 2017;**7**:4446.
- 35
- 36 18. Sileanu FE, Murugan R, Lucko N, et al. AKI in low-risk versus high-risk patients in
- 37 intensive care. *Clinical journal of the American Society of Nephrology : CJASN*
- 38 *2015*;**10**:187-96.
- 39
- 40 19. Liang KV, Sileanu FE, Clermont G, et al. Modality of RRT and Recovery of Kidney
- 41 Function after AKI in Patients Surviving to Hospital Discharge. *Clinical journal of the*
- 42 *American Society of Nephrology : CJASN* 2016;**11**:30-8.
- 43
- 44 20. Jung EM, Clevert DA, Schreyer AG, et al. Evaluation of quantitative contrast harmonic
- 45 imaging to assess malignancy of liver tumors: a prospective controlled two-center
- 46 study. *World journal of gastroenterology* 2007;**13**(47):6356-64.
- 47
- 48 21. Lichtenstein DA. BLUE-protocol and FALLS-protocol: two applications of lung
- 49 ultrasound in the critically ill. *Chest* 2015;**147**:1659-70.
- 50
- 51 22. Perera P, Mailhot T, Riley D, et al. The RUSH exam: Rapid Ultrasound in SHock in the
- 52 evaluation of the critically ill. *Emergency medicine clinics of North America*
- 53 *2010*;**28**:29-56.
- 54
- 55 23. Dietrich CF, Averkiou MA, Correas JM, et al. An EFSUMB introduction into Dynamic
- 56 Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion.
- 57 *Ultraschall in der Medizin* 2012;**33**:344-51.
- 58
- 59 24. Zhang Z. Univariate description and bivariate statistical inference: the first step delving
- 60 into data. *Annals of translational medicine* 2016;**4**:91.
25. Zhang Z. Model building strategy for logistic regression: purposeful selection. *Annals of*
- translational medicine* 2016;**4**:111.
26. Zhang Z, Zhang H, Khanal MK. Development of scoring system for risk stratification in
- clinical medicine: a step-by-step tutorial. Annals of translational medicine* 2017;**5**

- 1  
2  
3 27. Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in  
4 critically ill patients: the multinational AKI-EPI study. *Intensive care medicine*  
5 2015;**41**:1411-23.
- 6  
7 28. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international  
8 guidelines for management of sepsis and septic shock: 2016. *Intensive care*  
9 *medicine* 2017;**43**:304-77
- 10  
11 29. Bradley VE, Shier MR, Lucas CE, et al. Renal hemodynamic response to furosemide in  
12 septic and injured patients. *Surgery* 1976;**79**:549-54.
- 13  
14 30. Kosaka J, Lankadeva YR, May CN, et al. Histopathology of Septic Acute Kidney Injury: A  
15 Systematic Review of Experimental Data. *Critical care medicine* 2016;**44**:e897-903.
- 16  
17 31. May CN, Calzavacca P, Ishikawa K, et al. Novel targets for sepsis-induced kidney injury:  
18 the glomerular arterioles and the sympathetic nervous system. *Experimental*  
19 *physiology* 2012;**97**(11):1168-77.
- 20  
21 32. Cheng X, Wu B, Liu Y, et al. Incidence and diagnosis of Acute kidney injury in  
22 hospitalized adult patients: a retrospective observational study in a tertiary  
23 teaching Hospital in Southeast China. *BMC nephrology* 2017;**18**:203.
- 24  
25 33. Zhang Z, Lu B, Ni H, et al. Microalbuminuria can predict the development of acute  
26 kidney injury in critically ill septic patients. *Journal of nephrology* 2013;**26**:724-30.
- 27  
28 34. Zhang Z, Lu B, Sheng X, et al. Cystatin C in prediction of acute kidney injury: a systemic  
29 review and meta-analysis. *American journal of kidney diseases : the official journal*  
30 *of the National Kidney Foundation* 2011;**58**:356-65.
- 31  
32 35. Zhang Z, Xu X, Fan H, et al. Higher serum chloride concentrations are associated with  
33 acute kidney injury in unselected critically ill patients. *BMC nephrology*  
34 2013;**14**:235.
- 35  
36 36. Matejovic M, Ince C, Chawla LS, et al. Renal Hemodynamics in AKI: In Search of New  
37 Treatment Targets. *J Am Soc Nephrol* 2016;**27**:49-58.
- 38  
39 37. De Backer D, Donadello K, Sakr Y, et al. Microcirculatory alterations in patients with  
40 severe sepsis: impact of time of assessment and relationship with outcome. *Critical*  
41 *care medicine* 2013;**41**:791-99
- 42  
43 38. Dubin A, Pozo MO, Casabella CA, et al. Increasing arterial blood pressure with  
44 norepinephrine does not improve microcirculatory blood flow: a prospective study.  
45 *Critical care* 2009;**13**:R92
- 46  
47 39. Kanoore Edul VS, Dubin A, Ince C, et al. The microcirculation as a therapeutic target in  
48 the treatment of sepsis and shock. *Seminars in respiratory and critical care*  
49 *medicine* 2011;**32**:558-68.
- 50  
51 40. Post EH, Kellum JA, Bellomo R, et al. Renal perfusion in sepsis: from macro-to  
52 microcirculation. *Kidney international* 2017;**91**:45-60
- 53  
54 41. Holthoff JH, Wang Z, Seely KA, et al. Resveratrol improves renal microcirculation,  
55 protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-  
56 induced acute kidney injury. *Kidney international* 2012;**81**:370-78
- 57  
58 42. Lima A, van Rooij T, Ergin B, et al. Dynamic contrast-enhanced ultrasound identifies  
59 microcirculatory alterations in sepsis-induced acute kidney injury. *Critical care*  
60 *medicine* 2018;**46**:1284-92
43. Kalantarinia K. Novel imaging techniques in acute kidney injury. *Current drug targets*  
2009;**10**(12):1184-89

- 1
- 2
- 3
- 4 44. Schwenger V, Korosoglou G, Hinkel UP, et al. Real - time contrast - enhanced
- 5 sonography of renal transplant recipients predicts chronic allograft nephropathy.
- 6 American journal of transplantation 2006;**6**:609-15
- 7 45. Schneider AG, Hofmann L, Wuerzner G, et al. Renal perfusion evaluation with contrast-
- 8 enhanced ultrasonography. Nephrology Dialysis Transplantation 2011;**27**:674-81
- 9 46. Schneider AG, Goodwin MD, Bellomo R. Measurement of kidney perfusion in critically ill
- 10 patients. Critical care 2013;**17**:220
- 11 47. Calzavacca P, Evans RG, Bailey M, et al. Cortical and Medullary Tissue Perfusion and
- 12 Oxygenation in Experimental Septic Acute Kidney Injury. Critical care medicine
- 13 2015;**43**(10):e431-9.
- 14 48. Lankadeva YR, Kosaka J, Evans RG, et al. Urinary Oxygenation as a Surrogate Measure of
- 15 Medullary Oxygenation During Angiotensin II Therapy in Septic Acute Kidney Injury.
- 16 Critical care medicine 2018;**46**:e41-e48.
- 17 49. Fischer K, Meral FC, Zhang Y, et al. High-resolution renal perfusion mapping using
- 18 contrast-enhanced ultrasonography in ischemia-reperfusion injury monitors
- 19 changes in renal microperfusion. Kidney international 2016;**89**:1388-98
- 20 50. Evans RG, Ince C, Joles JA, et al. Haemodynamic influences on kidney oxygenation:
- 21 clinical implications of integrative physiology. Clinical and experimental
- 22 pharmacology & physiology 2013;**40**:106-22.
- 23 51. Harvey CJ, Sidhu PS, Bachmann Nielsen M. Contrast-enhanced ultrasound in renal
- 24 transplants: applications and future directions. Ultraschall in der Medizin
- 25 2013;**34**:319-21.
- 26 52. Rosado E, Riccabona M. Off-Label Use of Ultrasound Contrast Agents for Intravenous
- 27 Applications in Children: Analysis of the Existing Literature. Journal of ultrasound in
- 28 medicine : official journal of the American Institute of Ultrasound in Medicine
- 29 2016;**35**:487-96.
- 30 53. Rim SJ, Leong-Poi H, Lindner JR, et al. Quantification of cerebral perfusion with "Real-
- 31 Time" contrast-enhanced ultrasound. Circulation 2001;**104**(21):2582-7
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60




Figure 1: A color-coded map with circular regions of interest (ROIs) at the renal cortex and medulla.

106x73mm (300 x 300 DPI)




Figure 2: A color-coded graph comparing the quantitative contrast-enhanced ultrasound parameters between the groups with and without acute kidney injury. GOF: goodness of fit, BI: baseline intensity, AT: arrival time, TTP: time-to-peak, PI: peak intensity, AS: ascending slope, DT/2: descending time/2, DS: descending slope, AUC: area under the curve.

106x73mm (300 x 300 DPI)